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With the aging of the population,1 the number of chronically ill elderly persons will 
increase substantially. For example, in The Netherlands, the number of persons aged 
65 and over with type 2 diabetes in 2025 is estimated to have risen to 867.700 persons: 
a 58 percent increase compared with the situation in 2005.2 This increase of older 
persons with chronic somatic diseases will not only increase health care costs, but 
will also put further pressure on the health care system, in particular on primary care.3 
In order to reduce the pressure on the health care system, keeping patients in the 
best possible health status is important. Reducing disabilities and thus maintaining 
the highest possible quality of life are therefore important targets for patients with 
chronic diseases, as well as for health care providers. When the chronic disease leads 
to impairments and functional limitations, disabilities arise. These in turn result in 
difficulties in doing certain activities. This whole process is known as the disablement 
process.4 An existing disability may reinforce itself and eventually lead to a downward 
spiral. Factors like medical care and self-management skills or effective coping 
strategies may prevent the development of further functional limitations and disabil-
ity. There are also factors that may accelerate the disablement process; depression is 
one of them.5 
DEPRESSION AND ITS CONSEQUENCES 
Patients with a chronic somatic disease often face a major or minor depression. A 
major depression is characterised by the presence of at least five symptoms of 
depression during the same two-week period with at least one of the symptoms being 
depressed mood or loss of interest or pleasure (Table 1). The mental status should 
also cause significant distress or impairment in social, occupational, or other impor-
tant areas of functioning. Minor depression is a state in which two to four symptoms 
are present, one of them being depressed mood or loss of interest or pleasure. To 
date, minor depression is not an official separate DSM-IV diagnosis, but is only 
described in research criteria.6 The prevalence of depression in elderly is estimated to 
be 2% for major depression and 13% for minor depression.7 Further, the risk of 
depression is higher in persons with chronic somatic disease.8 For instance, in 
chronic obstructive pulmonary disease (COPD), overall prevalence rates range from 6 
to 42% for major depression and have been reported, and more than half of the 
COPD patients aged 65 or over reported high levels of depressive symptoms.9-11 In 
elderly diabetic patients, prevalence rates in elderly of up to 31% have been re-
ported.12 
Major depression is associated with a higher mortality,13 with increased physical 
disability,14 and with lower quality of life.15 Furthermore, major depression is associ-
ated with higher health care utilisation and higher medical costs and is one of the 
most costly diseases in today’s society.16 17 Depression further has a negative impact 
on adherence to treatment and is projected to be second in rank in the worldwide 
leading causes of disability in 2020.18 19 Even though minor depression is not recog-
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nised as a separate diagnosis and is not included in clinical guidelines, it is also 
known to have detrimental effects on mortality13 and quality of life.15 Patients with 
minor depression have a higher risk of developing a major depression20 21 and the 
likelihood of spontaneous remission in primary care is low (9 to 13%).22 Finally, the 
economic costs of minor depression are considerable and approach the costs of 
major depression.23 
 
Table 1  Symptoms of depression (DSM-IV) 
1. Depressive mood 
2. Loss of interest/ pleasure 
3. Significant weight loss/gain or changes in appetite 
4. Insomnia/ hypersomnia 
5. Fatigue/ loss of energy 
6. Feeling of worthlessness 
7. Psychomotor agitation/ retardation 
8. Problems concentration/ indecisiveness  
9. Recurrent thoughts of death 
 
In persons with a chronic disease, a co-occurring depression, whether major or 
minor, may pose a serious threat to a patients’ health status, as the chronic disease 
and depression may mutually reinforce each other. Patients may get depressed, when 
dealing with the consequences (disabilities) of their disease. In turn, the depression 
can make them less adherent to treatment regimens which may further affect their 
health status, leading to more complications that, in turn, bring more functional 
limitations and disabilities etc.4 18 In other words, the disablement process is rein-
forced. As patients with a chronic disease and co-occurring depression thus poten-
tially run the risk of sliding into a downward spiral, action is needed to break out of 
this spiral. 
RECOGNITION OF DEPRESSION 
A problem in dealing with depression in this population is that depression in chroni-
cally ill elderly patients is often not detected or treated.8 There are several explana-
tions for this phenomenon. Patients mainly go to their general practitioner (GP) for 
their somatic disease and depression has to – often unsuccessfully – ‘compete’ with 
somatic diseases for attention.24 Furthermore, somatic symptoms of depression may 
overlap with symptoms of the chronic somatic disease, making it more difficult to 
recognise the depression, as symptoms may be wrongly ascribed to the somatic 
disease. Moreover, because of the still existing stigma on mental health problems in 
elderly, older patients often do not express their depressive symptoms, because they 
perceive them as signs of weakness. And both GPs and patients sometimes feel that 
depression is a natural consequence of aging and illness and therefore does not 
require treatment.25 26 This attitude towards depression in old age is worrisome, given 
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the consequences of depression in chronically ill elderly patients, but especially since 
effective treatments for depression are available. 
DEPRESSION TREATMENT IN PRIMARY CARE 
Clinical guidelines for the treatment of depression in primary care recommend the 
use of antidepressants, psychological treatments, or combinations of the two.27 28 The 
choice of treatment is based on depression severity, experienced burden, and patient 
preference. As minor depression is not regarded a DSM-IV diagnosis, clinical guide-
lines do not recommend active treatment with antidepressants or psychological 
treatments for minor depression, but often recommend a watchful-waiting strategy.27-30 
Antidepressants are increasingly prescribed to elderly patients.31 32 The mechanism 
underlying antidepressants is that they increase the level of neurotransmitters (such 
as serotonin and norepinephrine) in the brain by preventing their reuptake. Effects on 
mood become visible after several weeks.33 Antidepressants, like tricyclic antidepres-
sants (TCAs) and the newer selective serotonine reuptake inhibitors (SSRIs), are 
equally effective in elderly patients, although it seems that TCAs have higher with-
drawal rates, due to side effects.34 
Psychological treatments include cognitive behavioural therapy (CBT) and self-
management approaches. Cognitive behavioural therapy (CBT) refers to therapies 
that aim to reduce dysfunctional emotions or behaviours by changing cognitions 
and/or behaviours.35 Depression, for example, is characterised by negative emotions 
and cognitions. These negative cognitions reinforce unhelpful behaviours (for 
example avoidance of certain situations), which in turn reinforce the negative 
cognitions. In CBT, links between dysfunctional cognitions and behaviours are 
identified and challenged. Through the use of new skills, such as problem solving, the 
patient explores alternatives for these cognitions and tries out new behaviour to test 
the accuracy of their cognitions and of alternatives. Repeated application of these 
newly acquired skills will lead to changes in behaviours and subsequently to changes 
in cognitions (reattribution). Once patients have broken with old cognitions and 
behaviours and have adopted new ones, depressive symptoms may reduce and 
patients are better armed against future episodes of distress and depression. Self-
management has many definitions and forms; Self-management for chronic condi-
tions often refers to methods, skills, and strategies by which patients can effectively 
manage (the consequences of) their disease in terms of daily functioning, and shares 
much of its theoretical background with CBT.36 37 Active self-managers take responsi-
bility for their own health status and are active participants in their own treatment. 
Three self-management tasks can be distinguished: 1) medical management, like 
adhering to medication and lifestyle rules, 2) role management, that involves main-
taining, changing and or developing new meaningful life roles, and 3) emotional 
management, referring to the way a person deals with the emotional consequences of 
INTRODUCTION 
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a disease. Skills to successful self-management include problem-solving, decision 
making, action planning, and self-tailoring.38 
DEPRESSION TREATMENT IN CHRONICALLY ILL ELDERLY PATIENTS 
Although the effectiveness of antidepressants has been shown in elderly patients,34 39 
antidepressant treatment in chronically ill elderly persons may nevertheless encoun-
ter problems, like non-adherence, side-effects, or problems arising from polyphar-
macy.40-42 Psychological treatments, on the other hand, do not have these problems. 
Psychological treatments have shown to be effective in reducing minor and major 
depression in elderly persons.43-45 The presence of a chronic somatic disease might 
complicate an effective treatment of depression. Several studies showed, however, 
that these psychological treatments work just as well in elderly with chronic somatic 
diseases.46-53 CBT appears as effective as antidepressants54 and has been shown to be 
more enduring than antidepressants,55 as patients learn skills that they continue to 
use throughout their lives. For chronically ill patients, having proper skills to deal with 
the consequences of their disease is important. Therefore, in chronically ill elderly 
persons with depression, psychological treatments providing these enduring skills 
may be preferable over antidepressants. These (short-term) psychological interven-
tions also seem appropriate for chronically ill elderly with minor depression. Al-
though watchful waiting is currently advised for minor depression, the intervention 
may nevertheless be helpful in minimizing depressive symptoms and reducing the 
risk of developing major depression in chronically ill persons. But above all, the skills 
they learn may also be of great benefit to them in the long term, when they face the 
consequences of their progressing chronic disease. 
Psychological treatments for depression are often not available within primary care 
settings. GPs may lack the necessary training or they do not have the time to adminis-
ter a psychological intervention. However, studies show that nurses can be success-
fully trained to administer psychological interventions, like CBT, to depressed 
patients.56 57 As primary care nurses in many countries are already involved in disease 
management programs for chronically ill patients and see patients on a regular basis, 
they are good candidates for the task of depression detection and for administering 
psychological interventions. In doing so, they can complement the care of the GP and 
may also reduce the burden on the GP. 
THE DELTA STUDY 
This thesis describes from the results of the DELTA study (Depression in Elderly with 
Long-Term Afflictions). The DELTA-study is a randomised controlled trial comparing a 
nurse-led led Minimal Psychological Intervention (MPI) with care as usual in 361 
elderly primary care patients. The MPI is based on CBT and self-management ap-
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proaches (role and emotional management) and is tailored to the patients’ needs. 
This skill-based intervention aims to reduce depressive symptoms through improving 
coping-skills and enhancing self-efficacy and mastery. Trained nurses administer the 
intervention. Participants had either diabetes mellitus type II (DM) or chronic ob-
structive pulmonary disease (COPD), and had a co-morbid depression. Patients were 
included in the DELTA-study if they had co-occuring minor depression, or mild or 
moderate major depression. Patients with severe major depression were excluded as 
the intervention was considered too short and minimal (1 to 10 sessions) for these 
cases.27 Patients were followed up to a year after inclusion. 
AIMS AND OBJECTIVES 
Main objective of this study was to evaluate both the effectiveness and cost-
effectiveness of the nurse-led Minimal Psychological Intervention (MPI) in reducing 
depressive symptoms and improving quality of life in elderly diabetic and COPD 
patients with a co-occurring minor to moderate depression. 
A second aim was to evaluate whether the effect of the MPI was generic across DM 
and COPD patients. Although chronic somatic diseases differ from each other in 
nature, symptoms, course, and consequences for daily life, patients with different 
chronic diseases probably face similar adaptive tasks and challenges in coping with 
their disease.38 58 Therefore, it was expected that the effect of an intervention aimed at 
reducing depression is generic across different diseases. 
A third aim was to evaluate relevant disease-specific outcomes for COPD patients and 
diabetic patients separately. 
A final objective addressed in this thesis was to validate the Patient Health Question-
naire-9 (PHQ-9) that was used for depression screening. Although this questionnaire 
has been validated in different populations, the recognition of depression in chroni-
cally ill elderly persons may be problematic given the potential overlapping of 
depressive symptoms with symptoms of chronic somatic disease, misconceptions of 
elderly persons about depression and the existing stigma on mental health problems 
in elderly, making persons reluctant to discuss their depressed mood. 
OUTLINE OF THIS THESIS 
Chapter 2 of this thesis addresses the study design and rationale of the DELTA-study. 
Chapter 3 reports on the reliability and validity of the screening instrument used in 
the DELTA-study, the Patient Health Questionnaire-9 (PHQ-9). For this purpose, 
additional data from a group of non-depressed patients were collected. In Chapter 4, 
the results on the effectiveness of the MPI on depressive symptoms and quality of life 
are presented. It is also examined whether or not the intervention is generic across 
DM and COPD patients. Chapter 5 and 6 report on the effects of the MPI on disease-
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specific outcomes for DM and COPD patients. In Chapter 5, the effects of the MPI on 
diabetes symptoms, diabetes-related emotional distress, and HbA1c-levels, an 
indicator of glycemic control, are described. Chapter 6 addresses the COPD patients, 
in whom depression and anxiety often co-occur. Both depressive symptoms and 
symptoms of anxiety, as well as COPD-specific quality of life were used as outcome 
measures. Chapter 7 reports on the cost-effectiveness of the MPI from a societal 
perspective. For this purpose, all relevant health care related costs as well as produc-
tion losses were collected. In Chapter 8, the results of the DELTA-study are discussed, 
including the limitations of the study and generalisability of the results. Recommen-
dations for future developments and research are also discussed. 
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ABSTRACT 
Background: Depression is a prevalent disorder in chronically ill elderly persons. It 
may decrease quality of life, and increase functional disability, medical costs, and 
health care utilisation. Because patients may slip into a downward spiral, early 
recognition and treatment of depression is important. Depression can be treated with 
antidepressants or psychological interventions; the latter can also be applied by 
trained paraprofessionals. 
In this paper, we describe the design of the DELTA study (Depression in Elderly with 
Long-Term Afflictions). The first objective of the DELTA study is to evaluate the 
effectiveness and cost-effectiveness of a minimal psychological intervention (MPI) to 
reduce depression in chronically ill elderly patients. The second objective is to 
evaluate whether a potential effect of the MPI may differ between types of chronic 
illnesses. The tailor-made intervention is administered by nurses, who are trained in 
the principles of cognitive behavioural therapy and self-management. 
Methods/Design: DELTA is a two-armed randomised controlled trial, comparing MPI 
to usual care. A total number of 180 patients with diabetes mellitus type II (DM) and 
180 patients with chronic obstructive pulmonary disease (COPD), who in addition 
suffer from non-severe depression, will be included in the study. In our study, non-
severe depression is defined as having minor depression, mild major depression or 
moderate major depression. The primary outcome measure is depression using the 
Beck Depression Inventory. Secondary outcome measures include quality of life, 
daily functioning, self-efficacy, autonomy, and participation. In the economic evalua-
tion, cost-effectiveness and cost-utility ratios will be calculated. Furthermore, a 
process evaluation will be carried out. 
Analyses will include both univariate and multivariate techniques and according to 
the intention to treat principle. The economic evaluation will be done from a societal 
perspective and data of the process evaluation will be analysed using descriptive 
techniques. 
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BACKGROUND 
Depression is a prevalent and disabling disorder, especially in patients with chronic 
illnesses, such as diabetes mellitus type II (DM) and chronic obstructive pulmonary 
disease (COPD). In older patients with DM, prevalence rates of clinical relevant 
depression range from 14 to 17%.1 2 In older patients with COPD, prevalence rates of 
25% for minor depression have been reported.3 Prevalence rates of major depression 
in older COPD patients range from 6 to 42%.4 
Persons suffering from minor or major depression have increased mortality risks and 
a decreased quality of life compared with non-depressed persons.5-7 Furthermore, 
depression has been shown to increase health care utilisation,8 9 medical costs,10 and 
disability.8 9 11 Since disability predicts the onset of depression and depression itself 
may further heighten risks of a progressing disability, this process of mutual rein-
forcement may lead to a downward spiral.11-14 In addition, depression impairs one’s 
ability to adhere to disease management regimens (diet, exercise, quitting smoking, 
taking medication regularly), potentially worsening the course of the chronic illness.15 
16 Hence, an early detection of depressive symptoms and treatment of depression is 
important in chronically ill elderly persons, thereby preventing or breaking a down-
ward spiral. In primary care however, depression often remains undetected.17 General 
practitioners have limited time and furthermore, current Dutch guidelines for DM 
and COPD don’t take into account the psychological consequences of the chronic 
illness. 
Available treatment options are antidepressants or psychological interventions. The 
effectiveness of antidepressants has been extensively studied and proven in major 
depression.18 Since there is no clear evidence of the effectiveness of antidepressants 
in minor depression,19 20 clinical guidelines advise against using antidepressants in 
minor depression.21 22 Cognitive therapy (CT) seems to be as effective as antidepres-
sants in severe depression,23 and also in patients with mild and moderate depres-
sion.24 Furthermore, CT seems to have an enduring effect.25 It is also increasingly 
recognised that chronically ill elderly suffering from depression might benefit from 
psychosocial support and improving coping skills, such as self-management tech-
niques.21 26 In a study with DM type II patients, cognitive behavioural therapy (CBT) in 
combination with supportive diabetes education proved to be an effective treatment 
for major depression.27 Similarly, self-management strategies in COPD patients have 
been reported to improve the patients’ health status and to reduce hospital admis-
sions.28 
Accumulating evidence shows that primary care staff can be trained in psychological 
interventions for depression.29 Several studies reported that practice nurses can 
successfully administer interventions to reduce depression in primary care settings.30 31 
We developed a minimal psychological intervention (MPI), based on principles of 
self-management and CBT. The intervention is administered by nurses and aims to 
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reduce non-severe depression in chronically ill elderly persons. Findings of a prior 
smaller pilot study showed that the intervention was feasible and acceptable to 
patients. Furthermore, the training programme, developed to teach nurses to admin-
ister the intervention, appeared to be feasible, attractive and successful among 
nurses.32 
In this contribution, we present the design of the DELTA study (Depression in Elderly 
with Long-Term Afflictions). The first objective of this randomised controlled trial 
(RCT) is to evaluate the effectiveness and cost-effectiveness of an MPI that is adminis-
tered by a nurse and aims to reduce non-severe depression in chronically ill elderly 
patients. The effects of the MPI are compared with usual care. The second objective is 
to evaluate whether a potential effect of the MPI is different between types of chronic 
illnesses. 
DESIGN AND METHODS 
Design 
The DELTA study is a two-armed randomised controlled trial, in which an effect 
evaluation, an economic evaluation and a process evaluation will be carried out. A 
total number of 360 patients will be included, 180 of which are patients with DM and 
180 are patients suffering from COPD. We chose DM and COPD because first, they 
are highly prevalent in primary care. Second, they have a different course and 
prognosis. DM can be seen a gradual progressive illness, whereas COPD as a gradual 
relapsing condition.33 This difference enables us to test whether the intervention is 
potentially generic. Approval for conducting this study was granted by the Medical 
Ethics Committee of the Maastricht University/ Academic Hospital Maastricht.  
Setting and recruitment 
In general practices in the southern part of Limburg, a province in the south of the 
Netherlands, all patients of 60 years and over with DM and or COPD were selected by 
the general practitioner, the general practitioner’s assistant, or the research assistant. 
Selection was made using ICPC codes (T90, R91.01, R95, R99.06) if possible and 
otherwise by medication prescriptions (those drugs which are most often prescribed 
by the general practitioner for these chronic illnesses). In the last phase of patient 
selection, the general practitioner applied the inclusion and exclusion criteria using a 
pre-coded form with checkboxes for each criterion (Table 1). 
All selected patients received a letter from their general practitioner with a request to 
complete a short screening questionnaire. This questionnaire, the Patient Health 
Questionnaire-9 (PHQ-9), consists of nine questions regarding the prevalence of 
symptoms of depression over the last two weeks. The response options are: “Not at 
all”, ”Several days”, “More than half the days” and “Nearly every day”. Its brevity and 
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the fact that it is a self-administered questionnaire make it a useful tool in screening 
for depression in primary care. The PHQ-9 has been validated for both diagnosing 
depression and measuring severity.34-36 Five questions on demographic variables were 
included in the questionnaire. Patients received a reminder by telephone two weeks 
after the questionnaire had been sent. All patients who scored at least 2 depressive 
symptoms at least at “more than half the days” and at least one of these symptoms 
was depressed mood or anhedonia, were invited to participate in an interview to 
confirm or reject the diagnosis of depression. The Mini International Neuropsychiat-
ric Interview (MINI) was used to confirm the diagnosis from the PHQ-9. The interview 
took place at the patient’s home and was administered by a trained nurse. The MINI is 
a validated and reliable diagnostic structured interview, covering 17 disorders based 
on DSM-IV criteria.37 38 An extra diagnosis box for minor depression was added to the 
MINI, based on the research criteria for minor depression as described in the DSM-
IV.39 Furthermore, the Hamilton Depression Rating Scale (HDRS) was used to deter-
mine the severity of the depression.40 41 Patients were excluded if they met one of the 
following criteria: if the MINI indicated a major depression in combination with a 
score above 18 (indicating a severe depression) on the HDRS, if the MINI indicated 
suicidal risk, or if the MINI indicated no depression at all (Table 1). Patients with a 
major depression and/or suicidal risk were referred back to their general practitioner. 
All remaining eligible patients (patients with a minor depression, non-severe major 
depression, or dysthymia) were invited to participate in the study and to give their 
informed consent. 
 
Table 1  Inclusion and exclusion criteria as applied by the general practitioner* or research nurse† 
Inclusion criteria: 
Established diagnosis of Diabetes Mellitus Type II or COPD* 
Age 60 years and over* 
Community dwelling* 
Minor depression or mild to moderate major depression according to MINI and HDRS criteria† 
Completed informed consent † 
Exclusion criteria: 
Treatment with antidepressants*† 
Severe major depression*† 
Major psychiatric problems (bipolar depression, schizophrenia, suicidal risk)*†  
Current psychosocial/psychiatric treatment* 
Serious cognitive problems (demential syndrome)* 
On waiting list for nursing home* 
Bedridden* 
Recent loss of spouse (< 3 months)* 
 
Randomisation 
After having signed the informed consent form, patients enrolled in the study and 
filled in the baseline questionnaire. After having completed the baseline question-
naire, patients were assigned to either the intervention or control group. Randomisa-
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tion was performed by an external agency using a computerized random number 
generator. In order to avoid an imbalance of chronic illness and general practice (care 
level) over the two groups, stratification for general practice and chronic illness (DM 
or COPD) was performed. Furthermore, to obtain equal numbers in both arms, a 
blocked design with a block size of two was applied. The intervention group received 
a Minimal Psychological Intervention, while the control group received usual care as 
given by their general practitioner, according to the guidelines for the specific 
chronic illness.  
Minimal Psychological Intervention 
The intervention was given by a trained nurse, at the patient’s own home. During a 
period of at most three months, patients received a maximum of 10 visits from the 
nurse. The number of visits depended on the patient’s progress. 
The Minimal Psychological Intervention contains elements from the Chronic Disease 
Self-Management Program (CDSMP) by Lorig and Gonzales,42 the Reattribution model 
from Goldberg43 and from the work of the project group of the Interventie Studie 
Eerste Lijn (INSTEL),44 as previously described.32 The intervention aims at teaching 
patients to take responsibility for day-to-day management of their illness and its 
consequences. In short, it consists of five phases: 
Phase 1: The nurse explores the patient’s cognitions on the origin of symptoms and 
complaints, and their relation to limitations and behaviour. 
Phase 2: The patient keeps a diary, where he or she records symptoms, complaints, 
thoughts, worries, related feelings, and behaviour. 
Phase 3: Using information from the diary, the nurse challenges the patient to link 
his or her mood and consequent behaviour to the course of the chronic ill-
ness. A distinction will be made between complaints related to the illness 
itself, and those related to the emotional and behavioural consequences of 
the illness. 
Phase 4: Introduction of the self-management approach by the nurse. The patient 
explores his or her possibilities to alter his or her behaviour. He or she then 
makes a plan on how to solve perceived problems and sets specific goals to 
be reached before the next visit from the nurse. 
Phase 5: Evaluation of the progress in achieving the goals. 
After a patient has completed these five phases successfully, he or she is supposed to 
be able to apply the self-management approach to any situation or problem he or she 
may encounter in the future. In consultation with the patient, the nurse can then 
decide to conclude the series of intervention visits.  
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The training program for nurses 
ADMINISTERING THE MINI 
In an 8h session, the nurses were trained how to confirm a diagnosis of depression by 
using the MINI and HDRS by a psychiatrist. 
APPLYING THE MINIMAL PSYCHOLOGICAL INTERVENTION 
During three 8h sessions, with 2-week intervals, four nurses were trained by two 
experienced trainers (a psychologist/cognitive behaviour therapist, and a general 
practitioner) on how to apply the intervention. In between training days, nurses 
practised their newly learned skills on a pilot patient. As mentioned earlier, the 
training program has been shown to be feasible, attractive and successful among 
nurses.32 Booster sessions were being held regularly during the study, and both a 
psychiatrist and a psychologist could be contacted by telephone to discuss cases at 
any time.  
Data collection 
Data was collected at five points in time: at baseline (T0), one week after the interven-
tion period (T1), and at three, six and nine months after the intervention period (T2, 
T3, T4) (Fig. 1). The intervention period for patients allocated to the intervention 
group varies from one week to three months. The intervention period of the control 
group is fixed at six weeks, which is estimated to be the mean duration of the inter-
vention period in the intervention group. Data were collected using self-administered 
questionnaires and cost diaries in combination with interviews by telephone.  
Effect evaluation 
Table 2 provides an overview of the measures of the effect and economic evaluation, 
and time of assessment. 
PRIMARY OUTCOME MEASURES 
The primary outcome measure in this study was level of depression, measured with 
the Beck Depression Inventory (BDI).45 46 The BDI consists of 21 items measuring 
symptoms of depression and has proven to be a valid and reliable too.47 
SECONDARY OUTCOME MEASURES 
Secondary outcome measures in the study were: Quality of life measured with the 
Short Form-36 (SF-36),48 disease-specific quality of life assessed with the Problem 
Areas in Diabetes questionnaire (PAID-1) for diabetes patients,49 and the St. George’s 
Respiratory Questionnaire (SGRQ) for patients with pulmonary disease.50 51 Further-
more, daily functioning was assessed with the Activities of Daily Life scale (ADL) from 
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the Groningen Activity Restriction Scale (GARS)52 self-efficacy assessed using the 12-
item Self-efficacy scale53 54 and autonomy and participation using the questions from 
the domain Autonomy outdoors from the Impact on Participation and Autonomy 
questionnaire (IPA).55 56 
COVARIATES 
Additionally, information on possible confounding factors and effect modifiers was 
collected. Information on demographic factors (age, gender, marital status, religion, 
education, occupation) was collected in the screening phase. Other factors measured 
are: coping using the active coping, avoidant coping and passive coping scales from 
the Utrecht Coping List (UCL),57 mastery using the Personal Mastery Scale developed 
by Pearlin and Schooler,58 anxiety assessed using the anxiety subscale from the 
Symptom Checklist (SCL-90)59 social support using the short version of the Social 
Support List- Interactions questionnaire (SSL-I),60 61 co-morbidity using the Chronic 
conditions list from Statistics Netherlands (CBS – Centraal Bureau voor de Statistiek), 
life events using a list of 16 life events where patients report which life events they 
have experienced in the past year, and how they value these events (positive, nega-
tive, or neutral). Personality was measured using scales for neuroticism and extraver-
sion from the Eysenck Personality Questionnaire (EPQ),62 severity of the chronic 
illness was assessed using the St. George’s Respiratory Questionnaire (SGRQ) for 
COPD patients,50 51 and the Diabetes Symptom Checklist – Revised (DSC-R) for 
diabetes patients.63 If possible, severity of the chronic illness will also be assessed by 
retrieving lung function (FEV1) and/or blood glucose levels (Hba1c) from hospital 
records or the general practitioner’s records at the end of the study Finally, smoking 
and body mass index (BMI) were assessed, and in order to check for contamination in 
the control group, two questions to check whether or not the patients in the control 
group had heard or benefited from the intervention were added to the questionnaire. 
Contamination of the control group may lead to a smaller difference in effect be-
tween intervention and control group. 
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Table 2  Outcome measures and time of assessment in the DELTA study 
Measure Moment in time      
Name questionnaire/variable Screening Baseline FU1 FU2 FU3 FU4 Other 
Marital status/living situation x - - - - - - 
Occupation/work situation x - - - - - - 
Education x - - - - - - 
Gender x - - - - - - 
Age x - - - - - - 
Religion x - - - - - - 
BDI - x x x - x - 
Euroqol (QALY’s)  - x x x - x - 
SF36 - x x x - x - 
SGRQ  - x x x - x - 
PAID-1  - x x x - x - 
ADL-scale from GARS - x x x - x - 
UCL  - x x x - x - 
Personal mastery scale  - x x x - x - 
Self-efficacy-scale  - x x x - x - 
IPA  - x x x - x - 
SCL-90 subscale anxiety - x x x - x - 
SSL-I 12 - x - - - x - 
CBS List Chronic conditions - x - - - x - 
Diabetes Symptom Checklist-Revised - x x x - x - 
Life-events  - - - - - x - 
EPQ - - x - - - - 
Year of diagnosis DM/COPD - x - - - - - 
Smoking - - - - - x - 
BMI - - - - - x - 
Contamination in control group - - - - - x - 
Direct costs within health care system - x x x x x - 
Direct costs outside health care system - x x x x x - 
Indirect costs outside health care system - x x x x x - 
Lung function – if available - - - - - - * 
Hba1c – if available - - - - - - * 
Process evaluation - - - - - - † 
Compliance (in process-evaluation)  - - - - - - ‡ 
FU= follow up 
* After intervention 
† During nurses training program and intervention period 
‡ During intervention period 
 
Economic evaluation 
A combined cost-effectiveness/ cost-utility analyses will be performed from a societal 
perspective. The BDI is used as primary outcome measure in the cost-effectiveness 
analyses. The primary outcomes measure for the cost-utility measure will be utilities 
based on the social tariff of the EuroQol.64 Health care costs, patient and family costs, 
as well as productivity losses will be recorded using cost diaries.65 Patients prospec-
tively kept the diary for two weeks at baseline and for four weeks at each follow up 
measurement. Afterwards, a telephonist contacted them to retrieve the information 
from the diary. Data were immediately entered in a computer file to ensure efficiency 
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and reliability. The costs of the intervention were separately calculated. For the 
valuation of health care costs and patient and family costs, the updated Dutch 
Guideline for costing in economic evaluations will be used.66 If no guideline costs 
existed, cost prizes were estimated using real costs and tariffs. For future costs and 
effectiveness data, a discount rate of 4% will be used. 
Process evaluation 
A process evaluation was carried out to assess the following outcomes. The reach of 
the intervention, defined as the proportion of the intended target population that 
actually participated in the intervention. The dose delivered was defined as the 
completeness of the intervention and number and duration of the intervention visit. 
Dose received, described in two concepts, namely exposure and satisfaction. Expo-
sure is the extent to which patients actively engage with and are receptive to the 
intervention, and satisfaction is defined as patient’s satisfaction with the interven-
tion.67 Barriers were described as the extent in which problems were encountered 
during the intervention. 
Data were collected using questionnaires filled out by nurses after every intervention 
visit, by means of checklists that were kept by the nurse for every patient to report 
which steps of the intervention had been taken, and by questionnaires filled out by 
patients after finishing the intervention. 
Analysis 
Data will be analysed according to the intention to treat principle. In addition, on 
treatment analyses will be performed. Changes in primary and secondary outcome 
measures between intervention and control group will be analysed using both 
univariate and multivariate techniques. Models will be adjusted for age, gender and 
socio-economic status (SES), and baseline differences. Potential additional confound-
ing factors and effect modifiers will be checked and, if necessary, included in the 
model. Since dependency between observations of subjects from the same general 
practice may exist as well as between repeated observations within persons, multi-
level analyses will also be carried out. All analyses will be performed for intervention 
and control group in total, as well as for DM and COPD separately. 
In the economic evaluation the cost and effects of care as usual and MPI by a practice 
nurse will be calculated and compared. The cost-effectiveness ratio will be stated in 
terms of costs per improvement on the BDI, the cost-utility ratio will focus on the net 
cost per QALY gained. Ratios will be determined for the total patient population as 
well as for COPD or DM patients separately. Bootstrapping will be used to estimate 
confidence intervals for calculated ratios. 
Descriptive statistics, Chi-square and t-tests will be used to analyse data from the 
process evaluation. 
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Figure 1  DELTA flowchart 
Q= questionnaire, 2w CD= two week cost diary, 4w CD=four week cost diary 
* First follow up takes place one week after the intervention period. In the intervention group, this 
may vary from 2 weeks to three months. In the control group, the intervention period is fixed at six 
weeks, which is estimated to be the mean duration of the intervention in the intervention group 
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Power calculation 
Assuming an α of 0.05, a 1 – β (power) of 0.90, a decrease of 18 percent of non-severe 
depression in the intervention group versus zero percent in the control group, 192 
persons were needed,68 48 COPD and 48 DM patients in the intervention group and 
48 COPD and 48 DM patients in the control group. We decided to recruit four groups 
of 90 patients (in total: 360), as we not only anticipated the potential need for sub-
group specific analyses, but also anticipated attrition varying between 20 and 30 
percent (e.g. due to refusals during the follow-up). 
DISCUSSION 
Progress of the study 
Based on experiences in the pilot study, we anticipated having to screen 3600 patients 
in order to include 360 patients. However, we had to increase the number of patients 
to be screened to reach this number. This was done because the percentage of 
patients eligible for the MINI interview was lower than in the pilot study. Further-
more, the percentage of patients refusing the MINI interview was higher than 
expected. To arrive at a gross number of 360 patients we had to screen a total number 
of 8326 patients. The response rate to the screening questionnaire was 67%. Eventu-
ally, 361 non-severely depressed patients were recruited in the study (DM: N=184; 
COPD: N=177). All interventions have been administered; currently follow-up data are 
being collected. Data collection will be complete in September 2006. 
Process evaluation 
First results of the process evaluation indicate that patients’ satisfaction with the 
intervention is high, and 96.5% of the patients who received the intervention reported 
to have benefited from the intervention. 
Future implementation 
If this intervention proves to be effective in reducing depression and improving 
quality of life and proves to be cost-effective, implementation of the intervention in 
the health care system is considered and anticipated. An implementation and dis-
semination plan has been developed and is being updated regularly to the latest 
insights. 
Acknowledgements 
We would like to thank Dr. Silvia Evers for her input in the sections about the eco-
nomic evaluation. This study was funded by the Netherlands Organisation for Health 
Research and Development (ZonMw), grant number 945-03-047. 
STUDY DESIGN 
 31 
REFERENCES 
1. Pouwer F, Beekman AT, Nijpels G, Dekker JM, Snoek FJ, Kostense PJ, et al. Rates and risks for co-morbid 
depression in patients with Type 2 diabetes mellitus: results from a community-based study. Diabetologia 
2003;46(7):892-8. 
2. Bruce DG, Casey GP, Grange V, Clarnette RC, Almeida OP, Foster JK, et al. Cognitive impairment, physical 
disability and depressive symptoms in older diabetic patients: the Fremantle Cognition in Diabetes Study. 
Diabetes Res Clin Pract 2003;61(1):59-67. 
3. Yohannes AM, Baldwin RC, Connolly MJ. Prevalence of sub-threshold depression in elderly patients with 
chronic obstructive pulmonary disease. Int J Geriatr Psychiatry 2003;18(5):412-6. 
4. van Ede L, Yzermans CJ, Brouwer HJ. Prevalence of depression in patients with chronic obstructive 
pulmonary disease: a systematic review. Thorax 1999;54(8):688-92. 
5. Spitzer RL, Kroenke K, Linzer M, Hahn SR, Williams JB, deGruy FV, 3rd, et al. Health-related quality of life 
in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study. Jama 
1995;274(19):1511-7. 
6. Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life: a population 
study. Diabetes Care 2004;27(5):1066-70. 
7. Penninx BW, Leveille S, Ferrucci L, van Eijk JT, Guralnik JM. Exploring the effect of depression on physical 
disability: longitudinal evidence from the established populations for epidemiologic studies of the eld-
erly. Am J Public Health 1999;89(9):1346-52. 
8. Katz I-R. On the inseparability of mental and physical health in aged persons: Lessons from depression 
and medical comorbidity. Am J Geriatr Psychiatry 1996;4(1):1-16. 
9. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a 
prospective epidemiologic survey. Jama 1990;264(19):2524-8. 
10. Katon WJ, Lin E, Russo J, Unutzer J. Increased medical costs of a population-based sample of depressed 
elderly patients. Arch Gen Psychiatry 2003;60(9):897-903. 
11. Penninx BW, Guralnik JM, Ferrucci L, Simonsick EM, Deeg DJ, Wallace RB. Depressive symptoms and 
physical decline in community-dwelling older persons. Jama 1998;279(21):1720-6. 
12. Geerlings SW, Beekman AT, Deeg DJ, Van Tilburg W. Physical health and the onset and persistence of 
depression in older adults: an eight-wave prospective community-based study. Psychol Med 
2000;30(2):369-80. 
13. Bruce ML, Hoff RA. Social and physical health risk factors for first-onset major depressive disorder in a 
community sample. Soc Psychiatry Psychiatr Epidemiol 1994;29(4):165-71. 
14. Bruce ML, Seeman TE, Merrill SS, Blazer DG. The impact of depressive symptomatology on physical 
disability: MacArthur Studies of Successful Aging. Am J Public Health 1994;84(11):1796-9. 
15. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on 
adherence, function, and costs. Arch Intern Med 2000;160(21):3278-85. 
16. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical 
treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 
2000;160(14):2101-7. 
17. Ormel J, Koeter MW, van den Brink W, van de Willige G. Recognition, management, and course of 
anxiety and depression in general practice. Arch Gen Psychiatry 1991;48(8):700-6. 
18. Wilson K, Mottram P, Sivanranthan A, Nightingale A. Antidepressant versus placebo for depressed 
elderly. Cochrane Database Syst Rev 2001(2):CD000561. 
19. Ackermann RT, Williams JW, Jr. Rational treatment choices for non-major depressions in primary care: an 
evidence-based review. J Gen Intern Med 2002;17(4):293-301. 
20. Oxman TE, Sengupta A. Treatment of minor depression. Am J Geriatr Psychiatry 2002;10(3):256-64. 
21. National Institute for Clinical Excellence. Depression. Managment of depression in primary and 
secondary care. London: NHS, NICE, 2004. 
22. van Marwijk HWJ, Grundmeijer HGLM, Bijl D, van Gelderen MG, de Haan M, van Weel-Baumgarten EM, 
et al. NHG-standaard Depressieve stoornis (depressie) (eerste herziening). Huisarts Wet 2003;46(11):614-
23. 
23. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, et al. Cognitive therapy vs 
medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005;62(4):409-16. 
CHAPTER 2 
  32 
24. Gloaguen V, Cottraux J, Cucherat M, Blackburn IM. A meta-analysis of the effects of cognitive therapy in 
depressed patients. J Affect Disord 1998;49(1):59-72. 
25. Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O’Reardon JP, et al. Prevention of 
relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychia-
try 2005;62(4):417-22. 
26. NIH consensus conference. Diagnosis and treatment of depression in late life. Jama 1992;268(8):1018-24. 
27. Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behavior therapy for depression in 
type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;129(8):613-21. 
28. Bourbeau J, Nault D, Dang-Tan T. Self-management and behaviour modification in COPD. Patient Educ 
Couns 2004;52(3):271-7. 
29. Moore RG. Improving the treatment of depression in primary care: problems and prospects. Br J Gen 
Pract 1997;47(422):587-90. 
30. Mynors-Wallis LM, Gath DH, Day A, Baker F. Randomised controlled trial of problem solving treatment, 
antidepressant medication, and combined treatment for major depression in primary care. Bmj 
2000;320(7226):26-30. 
31. Hunkeler EM, Meresman JF, Hargreaves WA, Fireman B, Berman WH, Kirsch AJ, et al. Efficacy of nurse 
telehealth care and peer support in augmenting treatment of depression in primary care. Arch Fam Med 
2000;9(8):700-8. 
32. Van Eijk JT, Diederiks JP, Kempen GI, Honig A, Meer Kv K, Brenninkmeijer WJ. Development and 
feasibility of a nurse administered strategy on depression in community-dwelling patients with a chronic 
physical disease. Patient Educ Couns 2004;54(1):87-94. 
33. Rolland JS. Chronic illness and the life cycle: a conceptual framework. Fam Process 1987;26(2):203-21. 
34. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ 
primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. Jama 
1999;282(18):1737-44. 
35. Lowe B, Spitzer RL, Grafe K, Kroenke K, Quenter A, Zipfel S, et al. Comparative validity of three screening 
questionnaires for DSM-IV depressive disorders and physicians’ diagnoses. J Affect Disord 2004;78(2):131-
40. 
36. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen 
Intern Med 2001;16(9):606-13. 
37. Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, Keskiner A, et al. The validity of the Mini 
International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. European 
Psychiatry 1997;12(5):232-241. 
38. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, et al. The Mini International 
Neuropsychiatric Interview (MINI): A short diagnostic structured interview: Reliability and validity ac-
cording to the CIDI. European Psychiatry 1997;12(5):224-231. 
39. American Psychiatric Association. DSM-IV-TR: Diagnostic and statistical manual of mental disorders. 
fourth edition, text revision ed. Washington DC: American Psychiatric Association, 2000. 
40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62. 
41. Hamilton M. Development of a rating scale for primary depressive illness. British journal of social and 
clinical psychology 1967;6(4):278-96. 
42. Lorig K, Gonzalez V. The integration of theory with practice: a 12-year case study. Health Educ Q 
1992;19(3):355-68. 
43. Goldberg D, Gask L, O’Dowd T. The treatment of somatization: teaching techniques of reattribution. J 
Psychosom Res 1989;33(6):689-95. 
44. van Os TW, Ormel J, van den Brink RH, Jenner JA, Van der Meer K, Tiemens BG, et al. Training primary 
care physicians improves the management of depression. Gen Hosp Psychiatry 1999;21(3):168-76. 
45. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of 
General Psychiatry 1961;4:561-571. 
46. Lustman PJ, Clouse RE, Griffith LS, Carney RM, Freedland KE. Screening for depression in diabetes using 
the Beck Depression Inventory. Psychosom Med 1997;59(1):24-31. 
47. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five 
years of evaluation. Clinical Psychology Review 1988;8(1):77-100. 
STUDY DESIGN 
 33 
48. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, 
and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease 
populations. J Clin Epidemiol 1998;51(11):1055-68. 
49. Snoek FJ, Pouwer F, Welch GW, Polonsky WH. Diabetes-related emotional distress in Dutch and U.S. 
diabetic patients: cross-cultural validity of the problem areas in diabetes scale. Diabetes Care 
2000;23(9):1305-9. 
50. Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med 1991;85 
Suppl B:25-31; discussion 33-7. 
51. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic 
airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992;145(6):1321-7. 
52. Kempen GI, Sullivan M, van Sonderen E, Ormel J. Performance-based and self-reported physical 
functioning in low-functioning older persons: congruence of change and the impact of depressive symp-
toms. J Gerontol B Psychol Sci Soc Sci 1999;54(6):P380-6. 
53. Bosscher RJ, Smit JH. Confirmatory factor analysis of the General Self-Efficacy Scale. Behav Res Ther 
1998;36(3):339-43. 
54. Sherer M, et al. The Self-efficacy Scale: Construction and validation. Psychological Reports 1982;51(2):663-
671. 
55. Cardol M, de Haan RJ, van den Bos GA, de Jong BA, de Groot IJ. The development of a handicap 
assessment questionnaire: the Impact on Participation and Autonomy (IPA). Clin Rehabil 1999;13(5):411-9. 
56. Cardol M, de Haan RJ, de Jong BA, van den Bos GA, de Groot IJ. Psychometric properties of the Impact on 
Participation and Autonomy Questionnaire. Arch Phys Med Rehabil 2001;82(2):210-6. 
57. Schreurs PJG, Willige van de G, Brosschot JF, Tellegen B, Graus GMH. De Utrechtse Coping Lijs: UCL; 
Omgaan met problemen en gebeurtenissen. Lisse: Swets en Zeitlinger B.V., 1993. 
58. Pearlin LI, Schooler C. The structure of coping. J Health Soc Behav 1978;19(1):2-21. 
59. Arrindel WA, Ettema JHM. SCL-90: Handleiding bij een multidimensionele psychopathalogie-indicator. 
Lisse: Swets en Zeitlinger B.V., 1986. 
60. Sonderen van E. Het meten van sociale steun met de Sociale Steun Lijst-Interacties (SSL-I) en Sociale 
Steum Lijst-Discrepanties (SSL-D); een handleiding. Groningen: Noordelijk Centrum voor Gezondheids-
vraagstukken (NCG), 1993. 
61. Kempen GIJM, Van Eijk LM. The psychometric properties of he SSL12-I, a short scale for measuring social 
support in the elderly. Social Indicators Research 1995;35(3):303-312. 
62. Sanderman R, Arrindell WA, Ranchor AV, Eysenck HJ, Eysenck SBG. Het meten van persoonlijkheidsken-
merken met de Eysenck Personality Questionnaire (EPQ): een handleiding. Groningen: Noordelijk cen-
trum voor Gezondheidsvraagstukken, Rijksuniversiteit Groningen, 1995. 
63. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM. Development of a type 2 diabetes symptom checklist: a 
measure of symptom severity. Diabet Med 1994;11(3):253-61. 
64. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35(11):1095-108. 
65. Goossens ME, Rutten-van Molken MP, Vlaeyen JW, van der Linden SM. The cost diary: a method to 
measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol 2000;53(7):688-95. 
66. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek, 
methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Diemen: Col-
lege voor zorgverzekeringen, Geactualiseerde versie 2004. 
67. Linnan L, Steckler A. Process Evaluation for Public Health Interventions and Research: An Overview. In: 
Steckler A, Linnan L, editors. Process Evaluation for Public Health Interventions and Research. San Fran-
cisco: Jossey-Bass, 2002:1-23. 
68. Potock S. Clinical trials: A Practical Approach. Chichester: John Wiley and Sons, 1983. 
 
CHAPTER 2 
  34 
 
VALIDITY PHQ-9 
 35 
 
 
 
Summed score of the Patient Health Questionnaire-9 
was a reliable and valid method for depression 
screening in chronically ill elderly patients 
 
 
 
Validity PHQ-9 
Chapter 3 
 
 
 
 
 
 
 
 
 
 
 
F Lamers, CCM Jonkers, H Bosma, BWJH Penninx, JA Knottnerus, JThM van Eijk 
Journal of Clinical Epidemiology, 2008;61(7):679-287 
Dit hoofdstuk is tot nader bericht van de promovendus verwijderd 
- Universiteitsbibliotheek Maastricht - 
EFFECT EVALUATION 
 55 
 
 
 
The effectiveness of a minimal psychological 
intervention in chronically ill elderly patients with 
depression: a randomised trial (the DELTA-study) 
 
 
 
 
Effect evaluation 
Chapter 4 
 
 
 
 
 
 
 
 
 
 
F Lamers, CCM Jonkers, H Bosma, GIJM Kempen, JAMJ Meijer, BWJH Penninx, JA Knottnerus, JThM van Eijk 
Submitted 
CHAPTER 4 
  56 
 
EFFECT EVALUATION 
 57 
ABSTRACT 
Background: Among older persons with chronic somatic diseases, depression often 
remains unrecognised and untreated in primary care.  
Aims: To evaluate the effectiveness of a nurse-led minimal psychological intervention 
(MPI) in chronically ill elderly persons with depression. 
Method: A randomised controlled trial, comparing the MPI with usual care in 361 
primary care patients. Patients were 60 years and older and had a minor depression or 
mild to moderate major depression and either had type II diabetes or chronic 
obstructive pulmonary disease.  
Results: Nine months after the treatment, patients receiving the MPI had fewer 
depressive symptoms (p=0.03) and higher odds of a substantial depression reduction 
(≥ 50%) relative to baseline values (OR 3.22; 95%CI 1.31-7.89) than controls. A positive 
effect was also found on quality of life in diabetic patients. 
Conclusions: The nurse-led MPI appears both a feasible and effective treatment for 
minor to moderate depression in chronically ill elderly persons. 
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Elderly patients with chronic somatic illnesses often have a co-occurring minor or 
major depression, but such depression often remains unrecognised or untreated in 
primary care.1 As depression may further worsen the patients’ prognosis, its treatment 
in chronically ill elderly patients is important. Several meta-analyses showed that 
psychological treatments, including cognitive behavioural therapy (CBT), are effective 
in the treatment of depression in older adults.2-4 Two studies on collaborative care 
further suggest that somatic comorbidity does not adversely affect the positive 
response5 6 and studies on psychological interventions (including CBT) or self-
management in chronically ill elderly patients found beneficial effects on various 
outcomes.7-12 Recent studies show that paraprofessionals, like nurses, can success-
fully be trained to administer forms of CBT and self-management strategies and thus 
may complement the general practitioner’s (GP) regular work.13 14 The aim of the 
DELTA study (Depression in Elderly with Long-Term Afflictions) was to evaluate the 
effectiveness of a nurse-administered Minimal Psychological Intervention (MPI) in 
reducing depressive symptoms in elderly primary care patients with type II diabetes 
mellitus (DM) or chronic obstructive pulmonary disease (COPD) and a co-occurring 
non-severe depression. 
METHODS 
Design 
The DELTA study (Depression In Elderly with Long-Term Afflictions) was a two-armed, 
pragmatic, randomised controlled trial with a baseline measurement (before ran-
domisation) and three follow-up measurements at one week and at three and nine 
months after the intervention period (trial registration: ISRCTN92331982). In contrast 
to an explanatory trial in which a treatment is compared to a placebo under ideal 
circumstances, we conducted a pragmatic trial, measuring effectiveness of the MPI in 
a setting that realistically reflects routine clinical practice. To achieve this realistic 
setting, we included a heterogenic population, consisting of both DM and COPD 
patients with depression severities that – if detected and treated – most commonly 
would be treated in primary care. The intervention group received the MPI, while the 
control group received care as usual. Time between baseline and the first-follow-up 
measurement depended upon the time it took to complete the tailor-made interven-
tion. In the control group, the first follow-up measurement was set at six weeks after 
baseline, which beforehand was estimated the mean duration of the intervention (in 
the intervention group). 
A block randomisation scheme was used with stratification for chronic illness and 
general practice. The block size was two, because we expected to include a small 
number of patients per general practice and wanted to have them equally distributed 
over groups. The researchers entered patients in a computer connected to an 
external agency, which performed the randomisation using a computerised random 
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number generator. All data were collected through self-administered questionnaires. 
Data entry was performed by researchers blinded for the allocation. Approval for the 
study protocol was obtained from the Medical Ethics Committee of Maastricht 
University / University Hospital Maastricht. A detailed description of the study 
protocol has been published elsewhere.15 
We hypothesized that the MPI, based on the principles of CBT and self-management, 
would be more effective in reducing symptoms of depression and increasing quality 
of life than care as usual. We also examined whether the type of chronic illness (DM 
or COPD) modified the effects of the MPI. Since patients with different chronic 
illnesses probably face similar problems in coping with their disease (or its conse-
quences) in daily life,16 17 we expected that the effect of the intervention would be 
generic across diseases. 
Participants and setting 
Between October 2003 and May 2005, participants with DM or COPD were recruited 
in 89 primary care practices in the south of the Netherlands. The decision to include 
DM and COPD patients was based on the fact that these prevalent diseases are mainly 
treated in primary care in the Netherlands. Patients who had been diagnosed by their 
GP with type II diabetes mellitus or COPD, who were aged 60 years or over, who were 
community-dwelling and who did not meet exclusion criteria (treatment with antide-
pressants for depression, major psychiatric problems (bipolar depression, schizo-
phrenia, alcohol or substance abuse), current psychosocial/psychiatric treatment, 
serious cognitive problems, on waiting list for nursing home, bedridden, loss of 
spouse within last three months, and not being fluent in Dutch) were sent the Patient 
Health Questionnaire (PHQ-9).18 Patients who reported having at least two symptoms 
present for more than half of the days, one of them being loss of interest or de-
pressed mood, were invited to a structured diagnostic interview for DSM-IV axis I 
disorders, the Mini International Neuropsychiatric Interview (MINI).19 The MINI was 
administered at the patients’ home by nurses who had been trained by a psychiatrist 
and a GP, and had regular booster sessions with the psychiatrist. Patients with minor 
depression, mild to moderate major depression or dysthymia, according to the MINI, 
were invited to participate in the trial. Patients with suicidal risk and patients with 
severe major depression, according to the Hamilton Depression Rating Scale 
(HDRS>18),20 were excluded and referred to their GP. Somatic symptoms on the 
Hamilton scale were assessed using an ‘etiologic’ approach; symptoms that could be 
accounted for by the chronic somatic illness would not be counted towards the 
depression. This is a recommended approach for the assessment of depression in 
persons with a physical illness.21 After signing an informed consent form and com-
pleting a baseline questionnaire, patients were randomly allocated to the MPI or to 
care as usual. In all, 361 patients (185 DM; 176 COPD) were randomised. Multi-
morbidities are common in elderly persons, as was indeed the case in our study: 11 
EFFECT EVALUATION 
 61 
patients stratified for DM also had COPD, and 23 patients stratified for COPD also had 
DM. 
Interventions 
Patients allocated to the intervention group received the MPI additionally to usual 
care. Table 1 lists the phases of the intervention; more details can be found else-
where.15 22 The intervention aims to educate patients to take responsibility for day-to-
day management of their own illness and its consequences. The intervention was 
delivered at the patient’s home by trained nurses. The nurse delivering the interven-
tion was a different nurse than the one administering the MINI. The intervention is a 
combination of CBT and self-management; reattribution of negative cognitions and 
problem solving were core elements of the intervention. The intervention is tailor-
made; during the study, patients received two to ten visits over a period of at most 
three months. The number of visits depended on their progress through the steps of 
the intervention; on average patients received four intervention visits, each lasting 
approximately one hour. On average, patients in the intervention group completed 
the intervention in ten weeks (mean 10.3 (SD 5.6)). To ensure that the nurses adhered 
to the protocol during the study, they were asked to keep checklists, covering all 
essential intervention steps, for each patient. Examination of these lists showed that 
nurses had adhered closely to the guidelines in the protocol.23 Patients allocated to 
the control group received care as usual for their somatic illness, according to the 
clinical guidelines of the Dutch College of General Practitioners. These guidelines 
encompass regular check-up of medical symptoms, but do not explicitly involve 
detection and treatment of depressive symptoms.24-26 Depression treatment next to 
the MPI during follow-up was uncommon and non-differential between the interven-
tion and control group. At the last follow-up phase, seven and one person in the 
control group received antidepressants or consulted a psychiatrist or psychologist, 
respectively, compared with four and six persons in the intervention group. Only 
after the follow-up, GPs were informed about which patients had participated in the 
trial. 
 
Table 1  Phases of the Minimal Psychological Intervention 
Phase Description 
1 The nurse explores the patient’s feelings, cognitions and behaviours 
2 The patient keeps a diary, where he or she records symptoms, complaints, thoughts, worries, related 
feelings, and behaviour 
3 The patient is challenged to link his or her mood to the consequent behaviour, using information from 
the diary 
4 The self-management approach is introduced. The patient explores possibilities to alter his or her 
behaviour and draws up an action plan 
5 Evaluation of progress in achieving the goals of the action plan 
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Main outcome measures 
The primary outcome measure was depression, using the Beck Depression Inventory 
(BDI).27 28 In addition to the continuous BDI score, a dichotomous BDI score to 
represent clinically relevant improvement was calculated. Improvement of depression 
was defined as an ≥ 50% reduction relative to the baseline BDI score.29 The secondary 
outcome measure was quality of life, using the Physical Component Score (PCS) and 
Mental Component Score (MCS) of the Short-Form 36 (SF-36).30 Missing items on the 
SF-36 and on the BDI were imputed using the individual mean score of items that 
were not missing in patients for whom at least 50% of items were available. The 
number of patients in whom imputation was not possible across measurements (T0-
T1-T2-T4) was two-zero-two-two for the BDI and 47-22-16-21 for the PCS and MCS; this 
was equally distributed over groups. Data on age, sex, and education, as covariates, 
were collected during the PHQ-9 screening. 
STATISTICAL ANALYSIS 
Assuming an α of 0.05, a 1 – β (power) of 0.90, including 2 x 96=192 patients (48 COPD 
and 48 DM patients in the intervention group and 48 COPD and 48 DM patients in the 
control group) would allow a minimum difference between groups of 18% in im-
provement (≥ 50% reduction relative to the baseline BDI score) to be detected.31 
These number would further allow the detection of a difference in BDI score of at 
least 3.57 points at the 5% significance level to be detected (power 0.9). Anticipating 
an attrition rate of approximately 30% and the potential need for sub-group analyses, 
we decided to recruit a gross number of 360 patients. 
All analyses were carried out according to a pre-established analysis plan on an 
intention-to-treat basis. Chi-square and t-tests were used to test the comparability of 
groups at baseline in terms of all outcomes and demographic variables. We used a 
mixed-model, repeated-measures ANCOVA to test for differences between groups at 
different points in time. We included seven fixed effects in our model (age, sex, 
education level, baseline value, treatment group, time, and the interaction term 
between treatment group and time). There was no support for general practice being 
an additional level. Several random effects and covariance matrices were then tested, 
using -2 log likelihood tests to decide which model had the best fit. Lastly, two-way 
and three-way interaction terms for group, time, and illness (DM or COPD) were used 
to test for effect modification by disease (p<0.10). A check for outliers was conducted, 
but no serious outlier influence was established. Percentages of improvement of 
depression score were calculated for both groups, and between-group differences 
were tested using Chi-square tests. Logistic regression was used to calculate odds 
ratios (ORs) for improvement, correcting for age, sex, level of education, time, and 
BDI baseline score. Additional per-protocol analyses were performed with interven-
tion patients who – according to an analysis of process data23 – had received the 
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complete intervention (n=136) and excluding nine control patients who responded 
positively to a check for contamination during the data collection. Finally, sensitivity 
analyses using the last value carried forward-method were done. These analyses gave 
similar results. 
RESULTS 
Figure 1 describes the patient flow and follow-up. In total, 8,326 patients with DM or 
COPD received the screening questionnaire, 67% of whom returned the question-
naire. Nine hundred and sixty-five patients were eligible for the diagnostic interview 
(17.3%). Of these patients, 221 (23%) refused to participate in the MINI or could not 
be reached. A comparison of participants (n=744) and non-participants (n=221) 
revealed no differences between these groups regarding gender, age, educational 
level, or PHQ-9 sum score. The 83 patients that were eligible, but who refused to 
participate in the trial, were more often female, older and were significantly lower 
educated. In total, 361 patients were randomised; 183 to the intervention and 178 to 
usual care. 
During the follow-up period, we had a dropout rate of 33%, as anticipated. The 
dropout rate was somewhat higher, but not significantly, in the intervention group 
than in the control group (37.7% vs. 29.8%, p-value 0.11). Overall, dropouts were on 
average 2.8 years older than non-dropouts (p-value<0.00), but they did not differ in 
baseline BDI depression scores (p-value 0.11). As shown in Table 2, the intervention 
and control groups were comparable in terms of baseline characteristics. 
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Figure 1  Patient flow and follow-up in the DELTA study 
Legend: First follow-up at one week after the intervention, second follow-up at three months after the 
intervention and third follow-up at nine months after the intervention. 
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Table 2  Comparability of intervention and control groups in terms of socio-demographic variables and 
baseline values of outcomes 
  Usual Care MPI P-value 
Variable  n=178 n=183  
Age, yrs (SD)  70.6 (6.8) 70.8 (6.5) .73 
Sex, No. (%)     
 Male 95 (53.4) 98 (53.6) .97 
 Female 83 (46.6) 85 (46.4)  
Chronic illness, No. (%)     
 Diabetes 94 (52.8) 91 (49.7) .56 
 COPD 84 (47.2) 92 (50.3)  
Education level*†, No. (%)     
 Low 60 (33.9) 64 (35.4) .55 
 Medium 46 (26.0) 54 (29.8)  
 High 71 (40.1) 63 (34.8)  
     
BDI, mean (SD)  17.7 (8.0) 17.1 (7.2) .47 
     
PCS, mean (SD)  34.2 (9.1) 34.4 (9.5) .81 
     
MCS, mean (SD)  36.9 (9.9) 37.8 (8.2) .38 
Abbreviations: SD, standard deviation; BDI, Beck Depression Inventory; PCS, Physical Component 
Score; MCS, Mental Component Score. 
* data missing from 3 respondents 
† Low refers to primary school only, medium refers to lower vocational training or lower general 
education, high refers to higher vocational training, secondary school, higher professional education 
and university training 
Range of the BDI is 0-63, with 0 as the most favourable outcome; PCS and MCS are standardised scores 
with a mean of 50 and a standard deviation of 10 in the US general population; higher scores are more 
favourable 
 
 
Results from the mixed-model ANCOVA analyses (Table 3) show that the intervention 
group had lower average BDI scores than the control group, indicating fewer depres-
sive symptoms, and this was consistently found at all three follow-up measurements. 
The difference between the intervention and control groups was significant at the 
second follow-up (mean BDI difference 1.61, F=3.860, df=1, 510, p-value<0.05) and the 
last follow-up (mean BDI difference 2.09, F=4.998, df=1, 270, p-value 0.03). The inter-
vention group consistently had higher scores for PCS and MCS than the control 
group, indicating better quality of life, but these differences did not reach statistical 
significance. A marginal difference for PCS was found at the second follow-up 
(F=3.326, df=1, 450, p-value 0.07). 
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Table 3  Outcomes on depression and quality of life at follow-up 
  Usual Care  MPI   Mean difference 
  N=178  N=183   (Usual care – MPI) 
  Mean (SE)* N† Mean (SE)* N† P-value Mean (95%CI)* 
BDI        
 After 1 week 17.17 (0.53) 135 16.18 (0.55) 127 .19 0.99 (-0.50 to 2.49) 
 After 3 months 17.49 (0.56) 125 15.88 (0.60) 111 <.05 1.61 (>0.00 to 3.22) 
 After 9 months 18.00 (0.64) 123 15.91 (0.68) 114 .03 2.09 (0.25 to 3.93) 
PCS        
 After 1 week 33.60 (0.57) 109 34.26 (0.58) 110 .42 -0.66 (-2.25 to 0.94) 
 After 3 months 33.31 (0.61) 102 34.89 (0.62) 101 .07 -1.58 (-3.28 to 0.12) 
 After 9 months 33.35 (0.70) 98 34.15 (0.70) 103 .43 -0.79 (-2.74 to 1.16) 
MCS        
 After 1 week 38.30 (0.86) 109 39.84 (0.86) 110 .21 -1.54 (-3.92 to 0.84) 
 After 3 months 38.15 (0.88) 102 39.06 (0.89) 101 .47 -0.90 (-3.36 to 1.55) 
 After 9 months 37.56 (0.89) 98 39.43 (0.88) 103 .14 -1.87 (-4.34 to 0.59) 
Abbreviations: SE, standard error; 95%CI, 95% confidence interval; BDI, Beck Depression Inventory; 
PCS, Physical Component Score; MCS, Mental Component Score. 
Range of the BDI is 0-63, with 0 as the most favourable outcome; PCS and MCS are standardised scores 
with a mean of 50 and a standard deviation of 10 in the US general population; higher scores are more 
favourable. 
*estimates from mixed-model regression analyses, corrected for age, sex, level of education, and 
baseline value of the outcome measure. 
† Data on education was missing for 2 persons 
 
 
No significant two-way or three-way product terms of disease with group and time 
were found in the analyses with BDI and PCS (data not shown). For MCS, there was a 
significant product term with disease. The group x disease term was significant (p-
value 0.08), indicating a different effect of the intervention in DM patients than in 
COPD patients. Table 4 presents the results of the MCS analyses stratified by disease. 
The stratified analyses revealed that in DM patients, the intervention group had 
higher overall scores on the MCS than the control group, with a statistically signifi-
cant difference at the last follow-up (mean MCS difference 3.85, F=5.324, df= 1, 268.62, 
p-value 0.02). For COPD patients, no effect on MCS was found. 
Table 5 shows improvement rates in depressive symptoms (≥ 50 reduction relative to 
baseline BDI score) and ORs for both groups. The intervention group had a signifi-
cantly higher improvement rate at the last follow-up than the control group, with a 
significant odds ratio (OR 3.22; 95%CI 1.31-7.89). No interaction between group and 
disease was found (data not shown). 
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Table 4  Outcomes of disease-stratified analyses of the Mental Component Scores 
  Usual Care  MPI   Mean difference 
  Mean (SE)* N Mean (SE)* N P-value (Usual care – MPI) 
DM       Mean (95%CI) 
 After 1 week 37.47 (1.18) 54 40.07 (1.19) 54 .12 -2.60 (-5.90 to 0.70) 
 After 3 months 37.15 (1.17) 55 39.94 (1.21) 52 .10 -2.80 (-6.11 to 0.51) 
 After 9 months 35.87 (1.17) 55 39.72 (1.19) 54 .02 -3.85 (-7.14 to -0.57) 
COPD        
 After 1 week 39.20 (1.25) 55 39.70 (1.22) 56 .78 -0.50 (-3.95 to 2.95) 
 After 3 months 39.35 (1.33) 47 38.22 (1.30) 49 .55 1.12 (-2.55 to 4.80) 
 After 9 months 39.67 (1.37) 43 39.22 (1.29) 49 .81 0.45 (-3.27 to 4.17) 
Abbreviations: SE, standard error; 95%CI, 95% confidence interval; DM, type II diabetes mellitus; 
COPD, chronic obstructive pulmonary disease 
MCS is a standardised score with a mean of 50 and a standard deviation of 10 in the US general 
population; higher scores are more favourable. 
*estimates from mixed-model regression analyses, corrected for age, sex, level of education, and 
baseline value of MCS. 
 
 
Table 5  Percentages and odds ratios for improvement* on the depression outcome. 
 BDI improvement rate  
 Usual care MPI OR (95%CI)† 
 N (%) N (%)  
After 1 week 10 (7.4) 8 (6.3) 0.58 (0.18-1.88) 
After 3 months 11 (8.7) 14 (12.4) 1.49 (0.58-3.84) 
After 9 months 9 (7.3) 20 (17.5)‡ 3.22 (1.31-7.89) 
*defined as a reduction of baseline BDI score by at least 50% 
†from logistic regression corrected for age, sex, educational level, time, and baseline BDI value; control 
group is reference category 
‡ P value .02 
 
DISCUSSION 
Our nurse-led intervention significantly reduced depressive symptoms in chronically 
ill elderly patients with minor or mild to moderate major depression at three and nine 
months after the intervention. BDI improvement rates were significantly higher in the 
intervention patients than in the controls at the last follow-up. Although we expected 
effects on quality of life in all patients, a significant effect was only found on the 
mental component score in DM patients at the last follow-up. 
Several aspects should be taken into account when interpreting our results. First, as 
expected, we had an overall dropout rate of 33%, with slightly more dropouts in the 
intervention group than in the control group, but this difference was not significant. 
In the analyses, however, we used a mixed model for repeated measures, which uses 
all available data for each patient. Although we can not completely rule out bias from 
attrition, the absence of differences in baseline BDI depression scores between drop-
outs and non-drop-outs and the fact that intervention and control group continued to 
be comparable over time, does not make attrition bias plausible. Second, blinding of 
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patients obviously was not possible, as we compared the intervention with usual care, 
as is often done in pragmatic trials.32 
The results of the depression outcome are in line with outcomes of previous studies 
evaluating psychological interventions in chronically ill elderly patients. Several 
smaller trials found that CBT,9 interpersonal counselling,8 and self-management,12 
reduced depression in chronically ill elderly, but one study only evaluated short-term 
effects and included both depressed and non-depressed patients.9 The PEARLS study 
evaluated a program including Problem Solving Therapy in chronically ill elderly 
persons with minor depression or dysthymia and found an OR of 5.2 for a 50% 
improvement of the depression score.7 Neither of the abovementioned studies, 
however, were performed in primary care settings, nor did these studies assign 
primary care nurses for the administration of the intervention.  
In our study, differences between groups in BDI score were relatively small, as were 
improvement rates. This illustrates how persistent depressive symptoms in elderly 
populations are.33 Nevertheless, BDI effect sizes were 0.26 at the second and 0.29 at 
the third follow-up (not tabulated), which can be regarded as small to medium-sized 
effects.34 Furthermore, the OR for BDI improvement at the last follow-up revealed a 
threefold higher probability of improvement in intervention patients than in controls. 
Also, in patient with diabetes, there were consistent positive intervention effects on 
quality of life, which reached statistical significance at the last follow-up, with a 
medium effect size of 0.45 (not tabulated).  
According to some, much of the effect of psychological treatments can be attributed 
to the effects of patients receiving extra attention.4 However, if the effects of our 
intervention were solely attributable to the extra attention, we would have expected 
to see an effect immediately at the first follow-up. However, we only found effects in 
the longer term. Since our intervention is a short cognitive behavioural skill-based 
program, the most plausible explanation is that patients gained skills and continued 
to apply them in daily life during the follow-up period. As a result, their depression 
did not deteriorate during follow-up, and as depressive symptoms in the control 
group slightly deteriorated over time, this led to significant differences at later follow-
up. It is not unlikely, that intervention patients will continue to improve over a longer 
time interval if patients continue to increase their skills and become more confident 
self managers. Two comparable studies also found that effects became more pro-
nounced during longer follow-up.8 11 12 
Trained nurses played a major role in our study, both in diagnosing depression and in 
administering the intervention at the patient’s home. However, incorporating the 
intervention in the disease and care management programs of primary care facilities 
in the Dutch setting will probably mean that patients will not be visited at home. 
Since patients with chronic illnesses already come to primary care facilities for their 
regular check-ups, this should not represent a barrier to patients. Furthermore, 
having practice nurses deliver the intervention has several advantages: they see 
individual patients on a regular basis, they are aware of the patients’ personal circum-
stances and health-related problems, they can be trained to assess depression using 
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diagnostic interviews,35 and more importantly, they can monitor a possible relapse of 
depression and take action if necessary. 
With the aging of the population in Western society, the number of elderly patients 
with a chronic illness is expected to increase. This will put further pressure on health 
care systems in general, and on primary care, in particular. It is important that patients 
do not fall victim to the negative consequences of a comorbid depression as well, as 
this may have a substantial adverse impact on the course of their somatic illness and 
hence on their quality of life. Therefore, early detection of depressive disorders in 
chronically ill elderly persons is important and screening methods should be incorpo-
rated in their regular care. Minimal interventions like our MPI, which (1) provide 
patients with the skills to cope with the consequences of their illness and their 
depressive symptoms, (2) can be incorporated in existing disease and care manage-
ment programs, and (3) can be administered by nurses (e.g. practice nurses), can play 
a major role in preventing further deterioration of patients and may help alleviate the 
burden on the health care system. The modest, but positive results from the current 
effectiveness study, and the positive results from an extensive process evaluation, 
revealing high patient satisfaction,23 strengthen our belief that the DELTA intervention 
may be well suited for implementation within existing disease and care management 
programs for DM and COPD in primary care. 
CONCLUSION 
Our relatively short psychological intervention, administered by a nurse, reduced 
depressive symptoms in chronically ill elderly patients with minor depression and 
mild to moderate major depression and improved quality of life in elderly DM 
patients. The intervention thus appears to have a generic effect on depression, but 
the effect on quality of life might be disease-specific. Given the findings from the 
current effectiveness-study (medium effect sizes and a pattern of increasing effects 
over longer time) and the positive results from process evaluation, opportunities for 
implementing the intervention in existing disease management programs should be 
explored, while awaiting results from the economic evaluation. Furthermore, patient 
characteristics and traits that predict response to treatment should be identified and 
recognition of depression in chronically ill elderly people in primary care should be 
further improved. To conclude, our intervention appears an effective and acceptable 
treatment for minor depression and mild to moderate major depression and may be a 
valuable addition to existing disease management programs for older patients. 
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ABSTRACT 
Objective: To determine whether depression treatment with a nurse-led minimal 
psychological intervention (MPI) improves diabetes-specific quality of life and 
glycemic control in elderly diabetes patients. 
Research Design and Methods: A pragmatic, randomised controlled trial was carried 
out comparing the MPI with usual care among 208 primary care patients of ≥60 years 
with type 2 diabetes and co-occurring minor to moderate depression. Assessment of 
diabetes-specific quality of life (symptom and emotional distress) was made at 
baseline, one week, and three and nine months after treatment. HbA1c levels were 
obtained from the records of general practices. 
Results: Only in higher-educated patients did the intervention have significant effect 
on both emotional and symptom distress. Further, we found an effect on symptom 
distress in men, and on emotional distress in patients with a shorter diabetes duration 
(<7 years). A significant trend over time for HbA1c was found in favor of the interven-
tion, with a significant difference in HbA1c after nine months. 
Conclusions: The intervention had limited effects on diabetes-specific quality of life. 
As only certain subgroups benefited (more highly educated persons, men, persons 
with DM durations of <7 years), ways of increasing effectiveness in these groups 
should be explored. The potentially beneficial effect on glycemic control needs 
further research. 
Trial registration: isrctn.org; identifier: ISRCTN92331982 
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Approximately 10 to 17% of all diabetes patients suffer from depression.1 2 Depression 
is associated with lower quality of life,3 4 non-adherence to medical regimens and self-
care behaviours,5 DM complications,6 and higher medical costs and health care 
utilization.7 Furthermore, depression has a negative impact on physical activity,5 and 
may reduce glycemic control through central nervous system regulatory changes.3 
Diabetes itself may negatively influence depression as poor glycemic control can 
induce negative moods,3 and physical illness is thought to be a predictor of poor 
depression outcome.8 Further, diabetes patients with co-occurring depression report 
more diabetes symptoms than those without.9 Given these reciprocal negative 
consequences, depression treatment is of vital importance to diabetes patients; it may 
improve self-care behaviours and thus help reduce the burden of diabetes in terms of 
diabetes-specific symptom and emotional distress.10 It may also improve glycemic 
control, as was found in a small-scale trial evaluating CBT.11 
We have previously shown that a nurse-led minimal psychological intervention (MPI) 
based on Cognitive Behavioral Therapy (CBT) and self-management principles 
reduced depressive symptoms and improved generic quality of life in elderly diabetes 
patients with co-occurring depression.12 In this paper, we evaluate whether the 
intervention also improves disease-specific quality of life and glycemic control. We 
expected that diabetes-specific quality of life in elderly diabetes patients with co-
occurring minor or mild to moderate major depression would improve, and that 
intervention patients would have better glycemic control than control patients. 
RESEARCH DESIGN AND METHODS 
We conducted a pragmatic randomised controlled trial approved by the Medical 
Ethics Committee of the Maastricht University/ University Hospital Maastricht. Details 
of the study protocol have been described elsewhere.12 13 Briefly, between October 
2003 and May 2005, patients were recruited from 89 primary care practices in the 
south of the Netherlands. First, all type 2 diabetes patients aged 60 years and over 
who did not meet the exclusion criteria were sent a depression screening question-
naire (Patient Health Questionnaire-9; PHQ-9).14 All patients who reported a) having at 
least two symptoms for more than half the time and b) one of these symptoms being 
loss of interest or depressed mood were invited to a diagnostic interview (n=534). A 
trained nurse interviewed the patient at home using the Mini International Neuropsy-
chiatric Interview (MINI)15 and the Hamilton Depression Rating Scale (HDRS).16 All 
patients with minor depression or mild to moderate major depression were invited to 
participate in the study. Patients with severe major depression (HDRS>18) or suicidal 
risk were referred to their general practitioner (GP). In total, 208 patients with type 2 
diabetes and minor depression or mild to moderate major depression signed in-
formed consent forms and completed a baseline questionnaire (Figure 1). Randomisa-
tion was then performed, blinded for the researchers, by an external agency using a 
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computerized random number generator with a block randomisation scheme 
stratified by general practice (block size of two). 
 
Intervention and usual care 
Patients allocated to the intervention group received the MPI at home in addition to 
usual care. The intervention is a nurse-administered, minimal psychological interven-
tion, consisting of elements of CBT and self-management. Its aim was to educate 
patients to take responsibility for the daily management of their own illness and its 
consequences. A detailed description of the intervention has been published else-
where.13 17 Nurses were trained by a GP, a psychologist, and a psychiatrist, and had 
regular booster sessions with the latter pair. The intervention is tailor-made: the 
number of visits depends upon progress. On average, patients had four intervention 
sessions of approximately one hour. A thorough process evaluation showed that the 
nurses adhered closely to protocol guidelines.18 Patients allocated to usual care 
received regular treatment according to the practice guidelines of the Dutch College 
of General Practitioners for type 2 diabetes. These guidelines include regular check-
ups for medical symptoms, but do not involve the detection and treatment of depres-
sive symptoms.19 Co-interventions such as pharmacological depression treatments 
were allowed, and considered non-differential between groups. GPs were informed 
about which patients had participated in the trial only after the follow-up.  
Data collection 
Information regarding age, sex and educational level was collected at the time of the 
PHQ-9 screening. Diabetes duration and use of insulin and oral hypoglycemic agents 
were assessed in the baseline questionnaire. 
Disease-specific quality of life was operationalized as diabetes-specific symptom 
distress assessed with the Diabetes Symptom Checklist – Revised (DSC-R),20 and 
emotional distress using the Problem Areas in Diabetes (PAID) questionnaire.21 Data 
were collected at baseline, one week and three and nine months after the treatment 
period. The PAID provides one total score; the DSC-R consists of a total score and 
subscores for eight dimensions: hyperglycemia, hypoglycemia, neuropathic pain, 
sensibility, fatigue, cognitive distress, cardiovascular symptoms, and ophthalmologic 
symptoms. Missing item scores on the DSC-R and PAID were imputed with the 
patient’s mean item score if at least 50% of the items had been completed. The 
number of patients for whom imputation was not possible ranged from 2 to 12 for the 
DSC-R and 3 to 12 for the PAID per measurement and was evenly distributed per 
group. 
After the follow-up period, all general practices were contacted in order to retrieve 
participants’ hemoglobin A1c (HbA1c) data determined between the inclusion phase 
and the end of the follow-up (response: 94%). Also, the medical records of patients 
EFFECTIVENESS IN DIABETES 
 79 
living within the Maastricht area were checked for HbA1c data at the University 
Hospital Maastricht. In total, we retrieved HbA1c data for 135 patients. 
 
Statistical analysis 
In the total DELTA study population (of which the 208 diabetes patients were a 
subgroup), the power calculation was based on improvement in depressive symp-
toms and has been described elsewhere.12 Based on an α=0.05 and β=0.9, 2x103 
patients are sufficient to detect a minimum clinically relevant difference of 0.72 on the 
DSC-R total score, 9.03 on the PAID and 0.59% for HbA1c. 
All analyses were conducted according to the intention-to-treat principle. Groups 
were checked for baseline comparability to identify potential confounders using Chi-
square and t-tests. Mixed-effect, repeated measures ANCOVA models were used to 
test the differences in DSC-R and PAID scores between groups at follow-up. Age, sex, 
educational level, treatment group, baseline value of outcome, time, and the product 
term of time and group were standard inclusions in the model, and diabetes medica-
tion and duration were added as they were found to confound the relation between 
groups and outcome (≥10% change in the estimate of group when added to the 
standard model). Furthermore, for significant differences, effect sizes (d) were 
calculated by dividing the difference in mean group scores by the pooled standard 
deviation.22 Additional per protocol analyses were done for the DSC-R and PAID, 
including patients who had received a complete intervention (i.e., all core steps of the 
intervention had been delivered, based on data from the process evaluation, n=67)18 
and excluding six control patients who responded positively to a contamination 
check during data collection. Further, last observation carried forward (LOCF) 
analyses were done. Possible influence from outliers was checked, but not observed. 
For HbA1c, we ran two models: one with the time of the HbA1c measurements on a 
continuous scale, and one with their time matched to that of the follow-up measure-
ments (baseline, one week, three and nine months after treatment). This was done on 
the condition that the HbA1c was determined within a six-week period around the 
follow-up measurement. Data from 70 patients (37 control and 33 intervention 
patients) who had both a baseline HbA1c and ≥1 follow-up measurements were used 
in analyses. The comparability of patients with and without HbA1c data available was 
checked and mixed-effect, repeated measures ANCOVA models were used (cor-
rected for age, sex, educational level, baseline HbA1c level and time). 
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Figure 1  Flowchart 
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RESULTS 
Figure 1 shows patient flow within the study. The 45 eligible patients who chose not 
to participate were significantly older than those who did. The dropout percentage 
throughout the follow-up was comparable between the intervention and control  
groups (33% vs. 30%, p=0.62). Dropout was associated only with higher age, with 
dropout characteristics not differing significantly between the intervention and 
control groups. Table 1 shows the baseline comparability of the groups. There were 
no significant differences at baseline. 
The intervention’s effects on quality of life in terms of symptom distress were limited 
(Table 2). Only at second follow-up did we find significant effects on the ophthalmo-
logic symptom subscale (group difference 0.83, p<0.01), on the cognitive stress 
subscale (group difference 0.72, p=0.03), and on the total DSC-R score (group differ-
ence 0.57, p<0.01). Effect sizes were medium: 0.45 for the ophthalmologic symptom 
subscale and total DSC-R score, and 0.38 for the cognitive stress subscale. For quality 
of life in terms of emotional distress (PAID), we found a consistent pattern in favor of 
the intervention, with a marginal significant difference after nine months (group 
difference 4.4, p=0.06). Per protocol and LOCF analyses yielded similar results. 
Patients for whom HbA1c values were available at baseline and at least one follow-up 
measurement (n=70) were more often female, and used insulin and insulin plus oral 
hypoglycemic agents significantly more often than patients without available HbA1c 
data (data not shown). This latter finding is not surprising as, according to clinical 
guidelines, HbA1c should normally be tested once a year, but in patients using insulin 
two to four times a day, it should be tested every three to six months 19. The interven-
tion patients showed an HbA1c decline over time, whereas the control patients 
experienced an increase. The difference between groups after nine months was 
statistically significant in favor of the intervention (group difference 0.5%, p=0.02). An 
additional analysis including the 70 patients with a baseline value, all available HbA1c 
observations (unmatched to the follow-up measurements) and time as a continuous 
variable further showed that the HbA1c trend over time differed significantly between 
groups (p<0.00). 
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Table 1  Comparability of intervention and control groups for socio-demographic and disease-related 
variables and baseline values of outcomes (n=208) 
  Usual care MPI P-value 
Variable  n=103 n=105  
Demographics     
Age, yrs (SD)  69.7 (6.6) 70.7 (6.6) 0.25 
Sex, no. (%)     
 Male 51 (49.5) 51 (48.6)  
 Female 52 (50.5) 54 (51.4) 0.89 
Education level*†, no. (%)     
 Low 34 (33.3) 35 (34.0)  
 Medium 26 (25.5) 26 (25.2)  
 High  42 (41.2) 42 (40.8) 0.56 
     
Disease-related variables     
Diabetes duration, yrs (SD)  9.8 (9.1) 8.2 (8.8) 0.22 
Medication‡, no. (%)     
 None 17 (16.8) 14 (14.3)  
 Oral hypoglycemic agents 47 (46.5) 60 (61.2)  
 Insulin & oral hypoglycemic agents 21 (20.8) 14 (14.3)  
 Insulin use 16 (15.8) 10 (10.2) 0.20 
     
Baseline values of outcomes     
DSC-R total, mean (SD)  2.8 (1.6) 2.9 (1.6) 0.88 
DSC-R subscales, mean (SD)    
 Hyperglycemic 3.5 (2.8) 3.4 (2.5) 0.88 
 Hypoglycemic 2.3 (2.1) 2.3 (2.1) 0.94 
 Polyneuropathic pain 2.3 (2.5) 2.1 (2.5) 0.65 
 Polyneuropathic sensory 2.4 (2.4) 2.4 (2.5) 0.88 
 Fatigue 5.3 (2.3) 5.1 (2.4) 0.52 
 Cognitive stress 3.2 (2.4) 3.0 (2.3) 0.63 
 Cardiovascular 2.4 (2.1) 2.6 (2.0) 0.62 
 Ophthalmologic symptoms 2.0 (2.3) 2.1 (1.9) 0.58 
     
PAID, mean (SD)  23.4 (19.5) 22.6 (20.5) 0.77 
     
HbA1c§, mean (SD)  7.2 (1.4) 7.5 (1.2) 0.36 
Abbreviations: SD, standard deviation; DSC-R, Diabetes Symptom Checklist – Revised; PAID, Problem 
Areas in Diabetes. DSC-R range is 0–10, with 0 being most favorable outcome; PAID range is 0–100, with 
0 being the most favorable outcome. 
* Low refers to primary school only, medium refers to lower vocational training or lower general 
education, high refers to higher vocational training, secondary school, higher professional education 
and university training 
† data missing from 3 patients 
‡ data missing from 9 patients 
§ based on data from 37 control patients and 33 intervention patients 
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Table 2  Diabetes-specific quality of life and glycemic control 
  Usual care 
 
 MPI 
 
  Mean difference 
(Usual care – MPI) 
  Mean (SE)* N Mean (SE)* N P-
value 
Mean (95%CI)* 
Symptom distress       
DSC-R Total       
 After 1 week 2.88 (0.14) 70 2.84 (0.16) 65 0.82 0.05 (-0.34 to 0.43) 
 After 3 months 3.24 (0.15) 69 2.67 (0.17) 59 0.006 0.57 (0.16 to 0.98) 
 After 9 months 2.71 (0.17) 60 2.75 (0.18) 59 0.85 -0.05 (-0.51 to 0.42) 
DSC-R Hyperglycemia       
 After 1 week 3.17 (0.25) 71 3.64 (0.27) 64 0.17 -0.48 (-1.16 to 0.20) 
 After 3 months 3.66 (0.25) 68 3.43 (0.28) 60 0.50 0.24 (-0.46 to 0.93) 
 After 9 months 2.88 (0.27) 61 3.39 (0.27) 63 0.15 -0.51 (-1.21 to 0.19) 
DSC-R Hypoglycemia       
 After 1 week 2.20 (0.22) 69 2.42 (0.23) 65 0.47 -0.22 (-0.81 to 0.37) 
 After 3 months 2.50 (0.22) 65 2.17 (0.24) 60 0.28 0.34 (-0.27 to 0.94) 
 After 9 months 2.05 (0.23) 60 1.85 (0.24) 58 0.52 0.20 (-0.42 to 0.2) 
DSC-R Pain       
 After 1 week 2.54 (0.25) 69 2.52 (0.27) 66 0.96 0.02 (-0.66 to 0.69) 
 After 3 months 2.91 (0.25) 67 2.68 (0.27) 61 0.50 0.24 (-0.45 to 0.92) 
 After 9 months 2.29 (0.26) 59 2.33 (0.27) 62 0.92 -0.04 (-0.74 to 0.66) 
DSC-R Sensory       
 After 1 week 2.33 (0.21) 68 2.58 (0.22) 66 0.37 -0.26 (-0.82 to 0.31) 
 After 3 months 2.92 (0.22) 67 2.43 (0.24) 61 0.11 0.48 (-0.11 to 1.08) 
 After 9 months 2.18 (0.18) 59 2.35 (0.26) 63 0.62 -0.17 (-0.85 to 0.51) 
DSC-R Fatigue       
 After 1 week 5.00 (0.21) 68 4.83 (0.23) 65 0.57 0.16 (-0.40 to 0.72) 
 After 3 months 4.91 (0.22) 67 4.65 (0.24) 59 0.40 0.26 (-0.34 to 0.86) 
 After 9 months 4.89 (0.26) 58 4.94 (0.28) 60 0.87 -0.06 (-0.77 to 0.65) 
DSC-R Cognitive stress       
 After 1 week 3.35 (0.23) 70 3.28 (0.25) 65 0.84 0.07 (-0.56 to 0.69) 
 After 3 months 3.63 (0.23) 67 2.91 (0.25) 60 0.03 0.72 (0.08 to 1.36) 
 After 9 months 3.16 (0.24) 60 2.98 (0.25) 58 0.58 0.18 (-0.46 to 0.83) 
DSC-R Cardiovascular       
 After 1 week 2.74 (0.19) 68 2.84 (0.21) 64 0.72 -0.10 (-0.61 to 0.42) 
 After 3 months 3.07 (0.19) 62 2.72 (0.22) 59 0.22 0.34 (-0.20 to 0.89) 
 After 9 months 2.53 (0.22) 62 2.74 (0.24) 58 0.50 -0.21 (-0.83 to 0.41) 
DSC-R Ophthalmologic      
 After 1 week 2.40 (0.22) 69 1.86 (0.24) 64 0.07 0.54 (-0.05 to 1.14) 
 After 3 months 2.52 (0.22) 69 1.69 (0.25) 58 0.008 0.83 (0.22 to 1.43) 
 After 9 months 2.22 (0.23) 61 1.96 (0.24) 57 0.40 0.27 (-0.35 to 0.88) 
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Table 2  Continued 
  Usual care 
 
 MPI 
 
  Mean difference 
(Usual care – MPI) 
  Mean (SE)* N Mean (SE)* N P-
value 
Mean (95%CI)* 
Emotional distress 
PAID       
 After 1 week 24.00 (1.62) 71 23.42 (1.73) 67 0.80 0.59 (-3.80 to 4.96) 
 After 3 months 23.56 (1.63) 69 21.49 (1.79) 60 0.37 2.07 (-2.44 to 6.58) 
 After 9 months 22.89 (1.72) 61 18.49 (1.76) 62 0.06 4.40 (-0.16 to 8.97) 
Glycemic control       
HbA1c        
 After 1 week 7.4 (0.2) 18 7.8 (0.2) 17 0.09 -0.4 (-0.9 to 0.1) 
 After 3 months 7.5 (0.2) 15 7.4 (0.2) 12 0.81 0.1 (-0.5 to 0.6) 
 After 9 months 7.8 (0.2) 17 7.3 (0.2) 20 0.02 0.5 (0.1 to 1.0) 
Abbreviations: SE, standard error; 95%CI, 95% confidence interval; DSC-R, Diabetes Symptom Checklist 
– Revised; PAID, Problem Areas in Diabetes. DSC-R range is 0–10, with 0 being most favorable outcome; 
PAID range is 0–100, with 0 being the most favorable outcome. 
*estimates from mixed-model regression analyses, corrected for age, sex, education level, diabetes 
medication and duration, and baseline value of outcome measure. HbA1c models corrected for age, 
sex, education level, and baseline value of HbA1c. 
 
As the intervention seemed to have little effect on symptom and emotional distress, 
we performed post-hoc analyses for the DSC-R total score and PAID to evaluate the 
effectiveness within subgroups. To the model, we added interaction terms per group 
of sex, age, education (tertiles), medication use and diabetes duration to the model. 
Where interaction terms were significant (p<0.10), stratified subgroup analyses were 
done. These additional analyses revealed that the intervention did have significant 
effects on symptom distress (DSC-R total score) on all follow-up measurements in 
male patients (group difference after nine months 0.7, p=0.01, d=0.99), but not in 
female patients (groups difference after nine months -0.9, p=0.01, d=-0.66). Further-
more, in patients with a diabetes duration of <7 years, the intervention group on 
average had more favorable scores for emotional distress (PAID) than the control 
group at all follow-up measurements, with a significant effect at second follow-up 
(group difference 6.6, p=0.04, d=0.39). In patients with a diabetes duration of ≥7 years, 
the intervention group scored more favorably only at the last follow-up. Distinct 
differences were also found for education on both symptom and emotional distress. 
In the lowest education tertile, intervention patients on average had worse outcomes 
than control patients, with effect sizes of -0.67 on the DSC-R and -0.65 on the PAID. In 
the middle and highest education tertiles, intervention patients benefited from the 
intervention and scored significantly higher than the control patients (Table 3). Effect 
sizes were large on the DSC-R; 1.22 for the middle tertile and 0.83-0.93 for the highest 
tertile. On the PAID, the effect size for the middle tertile was 0.77 and for the highest 
tertile 0.56. 
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Table 3  Diabetes-specific quality of life outcomes stratified by education level. 
 
 
Usual care MPI  Mean difference 
(Usual care – MPI) 
  Mean (SE)* N Mean (SE)* N P-value Mean (95%CI)* 
DSC-R Total 
Low        
 After 1 week 3.04 (0.32 22 3.56 (0.35) 20 0.24 -0.52 (-1.42 to 0.37) 
 After 3 months 3.31 (0.32 24 3.36 (0.38) 15 0.92 -0.05 (-.97 to 0.88) 
 After 9 months 2.42 (0.34 20 3.41 (0.39) 15 <0.05 -0.99 (-1.98 to -0.002) 
Medium        
 After 1 week 2.93 (0.21) 16 2.42 (0.22) 17 0.08 0.50 (-0.05 to 1.05) 
 After 3 months 3.51 (0.22) 17 2.41 (0.24) 16 <0.00 1.10 (0.51 to 1.70) 
 After 9 months 2.58 (0.30) 14 2.94 (0.29) 17 0.38 -0.36 (-1.17 to 0.46) 
High        
 After 1 week 2.91 (0.18) 32 2.59 (0.19) 28 0.19 0.33 (-0.16 to 0.81) 
 After 3 months 3.19 (0.19) 28 2.38 (0.20) 28 0.002 0.81 (0.30 to 1.31) 
 After 9 months 3.17 (0.21) 26 2.20 (0.20) 27 0.001 0.96 (0.42 to 1.51) 
PAID 
Low        
 After 1 week 22.88 (3.05) 22 31.97 (3.26) 20 0.04 -9.09 (-17.5 to -0.67) 
 After 3 months 19.71 (2.95) 24 23.52 (3.62) 15 0.40 -3.80 (-12.63 to 5.02) 
 After 9 months 20.97 (3.19) 19 21.33 (3.42) 17 0.94 -0.36 (-9.24 to 8.52) 
Medium        
 After 1 week 27.10 (3.59) 16 17.92 (3.54) 17 0.05 9.18 (-0.02 to 18.38) 
 After 3 months 28.92 (3.51) 17 18.07 (3.56) 17 0.02 10.85 (1.72 to 19.98) 
 After 9 months 22.67 (3.69) 15 14.09 (3.53) 17 0.07 8.58 (-0.68 to 17.85) 
High        
 After 1 week 24.85 (2.15) 33 20.62 (2.25) 30 0.15 4.23 (-1.52 to 9.98) 
 After 3 months 25.23 (2.26) 28 21.68 (2.33) 28 0.25 3.55 (-2.48 to 9.58) 
 After 9 months 25.47 (2.33) 27 18.78 (2.28) 28 0.03 6.69 (0.62 to 12.76) 
Low refers to primary school only, medium refers to lower vocational training or lower general 
education, high refers to higher vocational training, secondary school, higher professional education 
and university training. 
Abbreviations: SE, standard error; 95%CI, 95% confidence interval; DSC-R, Diabetes Symptom Checklist 
– revised; PAID, Problem Areas in Diabetes. DSC-R range is 0–10, with 0 being most favorable outcome; 
PAID range is 0–100, with 0 being the most favorable outcome. 
*estimates from mixed-model regression analyses, corrected for age, sex, education level, diabetes 
medication, duration of diabetes, and baseline value of outcome measure. 
CONCLUSION 
Overall, the nurse-led minimal psychological intervention had a moderate effect on 
disease-specific quality of life. Additional analyses revealed that it benefited symptom 
distress in men, but not in women, while emotional distress was more often improved 
in patients who had had diabetes for less than seven years. The most striking finding, 
however, was that patients within the lowest education tertile on average did not 
benefit from the intervention. Its effects on symptom and emotional distress were 
only found in the middle and highest education tertile, with medium to large effect 
sizes. Further, we found a difference in mean HbA1c level in favor of the intervention 
after nine months, with a significant difference between groups in trend over time. 
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Several aspects should be noted here. First, patients who dropped out were older 
than those who completed all questionnaires, but dropout was evenly distributed 
between treatment groups. Second, HbA1c data was obtained from general practices, 
and although the data give a good indication of the treatment effect, the number of 
observations was limited. HbA1c measurements in all patients at fixed points during 
the data collection would have provided stronger evidence. Third, the clinical 
relevance of the findings of the DSC-R and PAID is difficult to interpret as there is no 
clear definition of a clinically relevant difference. Both scales are said to be respon-
sive to change, but cut-off points for minimum clinically relevant differences are 
lacking.20 23 Finally, post-hoc analyses should be interpreted with caution as significant 
findings may have been the result of multiple testing. 
We found no effect on diabetes-specific quality of life in patients within the lowest 
education tertile. Previous studies evaluating the influence of socioeconomic status 
on response to MPI treatment also found diminished response in lower educated 
persons with respect to depressive symptoms.24 As patients with a lower socioeco-
nomic status already are at higher risk for diabetes complications,25 it is important to 
identify the factors related to this diminished response and evaluate the extent to 
which adaptations can be made to the intervention to improve its effectiveness for 
this group. The factors involved may range from intellectual ability and amenability to 
change in the patients’ cultural environment and perceived social support. Interest-
ingly, Areán and colleagues found that lower-income elderly persons experienced 
similar benefits on depression outcomes to those of the higher-income elderly from 
depression care management and problem-solving therapy. However, ongoing care 
management of up to a year was recommended for lower-income persons, as their 
physical functioning improved more slowly than that of higher-income patients.26 
These findings suggest that booster sessions or some other form of follow-up support 
in everyday self-management skills may improve outcomes for persons with lower 
socioeconomic status. 
The intervention’s effect on glycemic control is interesting, as most other studies 
have failed to find similar effects through depression treatment. Only a small trial by 
Lustman and colleagues showed that patients receiving CBT and education had 
significantly better glycemic control than those receiving education only.11 Two 
studies evaluating collaborative depression care for diabetes patients did not find 
effects on glycemic control despite depressive symptoms being reduced by enhanced 
care.10 27 Several smaller trials evaluating antidepressant treatment found either no 
effects 28 29 or adverse effects on glycemic control.30 However, whether a difference of 
0.5% is clinically relevant is debatable, although the lower the HbA1c is, the better. 
The suggestion that CBT-based depression treatments improve glycemic control is 
certainly worth further investigation on a larger scale with protocolized follow-up 
measurements. 
To conclude, although the effectiveness of the nurse-led minimal psychological 
intervention in reducing depressive symptoms and improving generic quality of life 
has been previously established, this intervention only improved diabetes-specific 
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quality of life in certain subgroups. As some patient groups did not benefit, ways of 
increasing the intervention’s beneficial effects in these groups, such as adding follow-
up meetings, should be explored. Likewise, the potentially beneficial effect of the MPI 
on glycemic control needs further examination. 
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ABSTRACT 
Background: Depression and anxiety are highly prevalent in elderly COPD patients. 
Since symptoms of depression and anxiety reduce quality of life in these patients, 
treatments aimed at improving mental health may improve their quality of life. Two 
advantages of psychological treatments are that they teach patients valuable and 
enduring skills, and that they can very well be administered by trained nurses. This 
study evaluated the effectiveness of a nurse-led Minimal Psychological Intervention 
(MPI) in reducing depression and anxiety, and improving disease-specific quality of 
life in elderly COPD patients. 
Methods: In a randomised controlled trial that was part of the Depression in Elderly 
with Long-Term Afflictions (DELTA) study, an MPI was compared with usual care in 
COPD patients. COPD patients aged 60 years or over, and with minor or mild to 
moderate major depression were recruited in primary care (n=187). The intervention 
was based on principles of cognitive behavioural therapy (CBT) and self-management. 
Outcomes were symptoms of depression (Beck Depression Inventory – BDI), symp-
toms of anxiety (Symptom Checklist – SCL), and disease-specific quality of life (Saint 
George’s Respiratory Questionnaire –SGRQ), assessed at baseline and at one week 
and three and nine months after the intervention. Mixed model, repeated measures 
ANCOVA was used to analyse outcomes. 
Results: Patients receiving the MPI had significantly fewer depressive symptoms 
(mean BDI difference 2.92, p=0.04) and fewer symptoms of anxiety (mean SCL differ-
ence 3.69, p=0.003) at nine months than patients receiving usual care. Further, mean 
SGRQ scores were significantly more favourable in the intervention group than in the 
control group after nine months (mean SGRQ difference 7.94, p=0.004). 
Conclusion: Our nurse-led MPI reduced symptoms of depression and anxiety and 
improved disease-specific quality of life in elderly COPD patients. The MPI appears to 
be a valuable addition to existing disease-management programmes for COPD 
patients. 
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INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a prevalent disease in elderly 
persons.1 Since COPD is irreversible, disabling and progressive, treatment aims to 
prevent deterioration of the disease and maintain a high quality of life. 
Depression and anxiety are highly prevalent in elderly COPD patients,2 3 and both are 
known to reduce quality of life.4-6 Since COPD is characterized by systemic inflamma-
tion,7 and depression is known to have an adverse influence on immunologic proc-
esses,8 9 co-occurrence of COPD and depression may lead to further deterioration of 
patients’ health status due to interaction. Breaking through this downward spiral is 
thus an important step towards improving quality of life. In view of the relationship 
between quality of life and depression and anxiety, treatments to reduce depression 
and anxiety in COPD patients may also improve their quality of life.3 10 
Depression and anxiety can be treated with antidepressants,3 11 12 although some claim 
that the evidence for their effectiveness in older COPD patients is sparse and incon-
clusive.11 13 Furthermore, treatment with antidepressants may be complicated by 
problems like medication side effects or refusal of treatment by COPD patients.11 13 
Psychological and self-management interventions may be better alternatives, espe-
cially as they teach patients valuable and enduring skills to cope with their disease, 
thus potentially ensuring a more lasting effect, extending beyond the end of treat-
ment. Furthermore, these interventions can be administered by trained paramedical 
professionals, like nurses, complementing the care of physicians.14 15 Few trials have 
assessed the effectiveness of psychological and self-management interventions in 
elderly COPD patients in terms of reducing symptoms of depression and anxiety. A 
recent systematic review based on four, relatively small, studies, found only limited 
evidence for the effectiveness of cognitive behavioural therapy (CBT) in reducing 
anxiety and depression in COPD patients, although the direction of treatment effects 
on both depression and anxiety scales mainly favoured CBT.16 A recent review of self-
management education for COPD patients produced inconclusive results for the 
effect on the generic quality of life outcome, but found significant effects on a 
disease-specific quality of life measure.17 Both reviews recommend further research 
into CBT and self-management for COPD patients. 
We have developed a nurse-administered minimal psychological intervention (MPI) 
based on the principles of CBT and self-management. The intervention has previously 
been evaluated in the Depression in Elderly with long-Term Afflictions (DELTA) study 
in a population of elderly patients with diabetes or COPD.18 The current contribution 
reports on the effect of the MPI on disease-specific quality of life and symptoms of 
depression and anxiety in the subgroup of elderly COPD patients with co-morbid 
depression. We hypothesized that our MPI would reduce symptoms of depression 
and anxiety and would also improve disease-specific quality of life. 
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MATERIALS AND METHODS 
Study design 
Detailed information on the study protocol has been published elsewhere.18 19 Briefly, 
a randomised controlled trial was conducted, with patients allocated to either the MPI 
or care as usual after signing informed consent. Self-administered questionnaires 
were used to collect data at baseline and at one week and three and nine months 
after the treatment period. Data entry was performed by researchers blinded for the 
allocation. Approval for this study was obtained from the Medical Ethics Committee 
of Maastricht University / University Hospital Maastricht.  
Participants and procedures 
Between October 2003 and May 2005, patients were recruited in 89 general practices 
in the south of the Dutch province of Limburg. We first selected all patients aged 60 
years and older with an International Classification of Primary Care (ICPC) code for 
emphysema / COPD or chronic bronchitis. If ICPC codes were not available, lists of 
patients with repeat prescriptions for bronchodilatory drugs were obtained. The 
patients’ general practitioners (GPs) then excluded from this initial broad selection all 
patients who did not have COPD, were bedridden, were on a waiting list for a nursing 
home, had major depression, used antidepressants, had major psychiatric conditions 
or were currently receiving psychosocial/psychiatric treatment, had serious cognitive 
problems, had recently lost their spouse or were not fluent in Dutch. All remaining 
patients aged 60 years and older who did have COPD according to their GP were sent 
a depression screening questionnaire (Patient Health Questionnaire-9 - PHQ-9).20 
After the PHQ-9 screening, all patients who reported having at least two symptoms of 
depression, one being loss of interest or depressed mood, were invited to a diagnos-
tic interview, consisting of the Mini International Neuropsychiatric Interview (MINI)21 
and the Hamilton Depression Rating Scale (HDRS).22 The interview was conducted at 
the patients’ home by a trained nurse. Patients with minor depression, mild major 
depression, moderate major depression or dysthymia were included in the study. 
Patients with severe major depression according to the HDRS (HDRS>18) and patients 
with suicidal risk were excluded and referred back to their GP. All COPD patients thus 
included (n=187) signed an informed consent form and were randomised. The 
researchers entered patients into a computer connected to an external agency, which 
performed the randomisation using a computerized random number generator. A 
block randomisation scheme was used, stratified for general practice. Block size was 
set at two, as we expected to include only a small number of patients per practice.  
EFFECTIVENESS IN COPD 
 97 
Intervention and usual care 
Patients allocated to the intervention group received the MPI at home, supplementary 
to usual care according to the clinical Guidelines for the Treatment of COPD of the 
Dutch College of General Practitioners.23 The intervention is a nurse-administered, 
minimal psychological intervention, consisting of elements of CBT and self-
management. Nurses were trained by a GP, a psychologist and a psychiatrist, and had 
regular booster sessions with the psychiatrist. The intervention was tailored to 
individual patients. Depending upon progress, patients received two to ten visits over 
a period of at most three months. Patients had on average four intervention contacts, 
each lasting approximately one hour. Table 1 lists the five phases of the intervention; 
a more detailed description of the intervention has been published elsewhere.19 24 To 
ensure that the nurses adhered to the protocol during the study, they were asked to 
keep checklists, covering all essential intervention steps, for each patient. Examina-
tion of these lists showed that nurses had adhered closely to the guidelines in the 
protocol.25 Patients allocated to the control group received care as usual according to 
the above-mentioned clinical guidelines. 
 
Table 1  Phases of the Minimal Psychological Intervention (MPI) 
Phase Description 
1 The nurse explores the patient’s feelings, cognitions and behaviours 
2 The patient keeps a diary, where he or she records symptoms, complaints, thoughts, worries, related 
feelings and behaviour 
3 The patient is challenged to link his or her mood to the consequent behaviour, using information 
from the diary 
4 The self-management approach is introduced. The patient explores possibilities to alter his or her 
behaviour and draws up an action plan 
5 Evaluation of progress in achieving the goals of the action plan 
 
Outcome measures 
Data were collected by means of self-administered questionnaires. Depressive 
symptoms were assessed using the Beck Depression Inventory (BDI)26 and anxiety 
was assessed using the anxiety subscale of the Symptom Checklist-90 (SCL).27 Demo-
graphic information was collected at the time of the PHQ-9 screening. Disease-
specific quality of life was assessed using the Saint George’s Respiratory Question-
naire (SGRQ).28 The SGRQ consists of a total score that summarizes the overall impact 
of COPD on health status, and three subscales: the activity scale (activities that cause 
or are limited by breathlessness), the impact scale (social functioning and psychologi-
cal disturbances) and the symptom scale (effects, frequency and severity of respira-
tory symptoms). Missing item scores on the SGRQ and SCL were imputed according 
to the recommendations in their respective manuals; missing items on the BDI were 
imputed with the patient’s mean item score as long as at least 50% of the items had 
been completed.  
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Analysis 
The power calculation for the DELTA study was based on the BDI in the total group of 
diabetes and COPD patients.18 According to this calculation, assuming an α of 0.05 
and a 1 – β (power) of 0.90, we needed to include 2 x 96=192 patients (48 COPD and 48 
DM patients in the intervention group and 48 COPD and 48 DM patients in the 
control group) to allow us to detect a minimum clinically relevant difference of 18% in 
improvement (≥50% reduction of BDI score relative to baseline).29 Anticipating an 
attrition rate of approximately 30% and the potential need for subgroup analyses, we 
decided to recruit a gross number of 360 patients. In the group of COPD patients 
included in the current study (n=187), a difference of 7.83 on the SGRQ total score 
would be significant at the 5% level. A difference of four points on the SGRQ is 
considered clinically relevant. 
Analyses were based on the intention-to-treat principle. The comparability of groups 
was checked by means of t-tests and Chi-square tests for demographic and outcome 
variables. Mixed model, repeated-measure ANCOVA analysis was used to test the 
differences between groups at follow-up measurements. Advantages of mixed model 
analysis include that it can handle missing observations, and error terms are esti-
mated more precisely, thereby further increasing power. Fixed effects included in the 
model were: age, gender, educational level, treatment group, baseline value of 
outcome, time and the product term of time and group. Several random effects and 
covariance matrices were tested, using -2 log likelihood tests to decide which model 
had the best fit. Maximum Likelihood models were then run, whose results are 
presented here. 
In addition, effect sizes (d) were calculated by dividing the difference in mean group 
scores by the pooled standard deviation.30 The percentage of patients showing an 
improvement of four points on the SGRQ total score was also computed and differ-
ences between groups were tested with Chi-square tests. 
Additional per-protocol analyses were done, including patients who had received a 
complete intervention (all core steps of the intervention delivered, based on nurses’ 
checklists, n=60 25) and excluding four control patients who had received information 
on the content of the intervention and had benefited from this (based on self-report). 
We also performed analyses in which missing observations were imputed (last 
observation carried forward - LOCF). 
RESULTS 
Figure 1 shows the flow of COPD patients in the trial. Of the 500 patients invited for a 
MINI, 164 did not meet the inclusion criteria. The 41 patients who were eligible but 
refused to participate were significantly older than patients who did enter the study. 
Of the 187 patients who were included, 96 were offered the MPI, and 91 received 
usual care. The dropout-rate was 36%, which was slightly higher than the anticipated  
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Figure 1  Flowchart 
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30%. Although the difference was not statistically significant, the dropout-rate was 
somewhat higher in the intervention group than in the control group (40% vs. 33%, 
p=0.35). Furthermore, dropouts overall had a higher age and higher baseline BDI and 
SGRQ scores (activity and impact subscales and total score), indicating worse depres-
sion states and lower quality of life (data not shown). 
Table 2 shows the comparability of groups at baseline. None of the differences 
between the intervention and control groups were statistically significant, although 
the control group was slightly older and had a somewhat higher educational level 
than the intervention group. In addition, the control group had somewhat higher 
mean BDI and SGRQ total scores, indicating a higher level of depressive symptoms 
and lower quality of life than the intervention group. 
Results of the mixed model analyses are presented in Table 3. On average, we found 
significantly lower scores for both the depression and anxiety outcomes at nine 
months in the intervention group compared with the control group, indicating fewer 
symptoms (BDI p=0.04; SCL p=0.003). As for disease-specific quality of life, we found 
that the intervention group had significantly better scores on the SGRQ activity  
 
Table 2  Comparability of MPI intervention and control groups regarding socio-demographic variables 
and baseline values of outcomes 
  Usual care MPI P-value 
Variable  n=91 n=96  
Age, yrs (SD)  71.5 (7.1) 70.5 (6.3) 0.32 
Sex, No. (%)     
 Male 53 (58.2) 59 (61.5)  
 Female 38 (41.8) 37 (38.5) 0.65 
Education level†, No. (%)     
 Low 31 (34.1) 36 (37.5)  
 Medium 24 (26.4) 31 (32.3)  
 High 36 (39.6) 29 (30.2) 0.39 
     
BDI, mean (SD)  18.3 (7.2) 17.1 (6.5) 0.23 
     
SCL, mean (SD)  20.4 (7.3) 20.6 (6.2) 0.83 
     
SGRQ total score, mean (SD)  56.8 (19.5) 54.9 (17.5) 0.55 
     
SGRQ activity, mean (SD)  70.9 (21.0) 70.6 (20.9) 0.79 
     
SGRQ impact, mean (SD)  46.2 (22.3) 45.9 (20.8) 0.91 
     
SGRQ symptoms, mean (SD)  56.7 (27.5) 60.9 (25.2) 0.30 
† Low refers to primary school only, medium refers to lower vocational training or lower general 
education, high refers to higher vocational training, secondary school, higher professional education 
and university training 
Range of the BDI is 0-63, with 0 as the most favourable outcome; range of SGRQ total scale and 
subscales is 0-100, with 0 as the most favourable score; range of the SCL Anxiety scale is 1-50, with 1 as 
the most favourable outcome. 
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subscale than controls at one week (p=0.004) and three months (p=0.02) after the 
intervention, but the mean difference between groups was no longer significant at 
nine months after the intervention (p=0.09). Results for the SGRQ impact subscale-
showed the opposite pattern: there were no significant differences immediately after 
the intervention, but the intervention group had significantly better scores than the 
control group at three months (p= 0.02) and nine months (p=0.003) after the interven-
tion.  
 
Table 3  Outcomes on quality of life, depression and anxiety 
  Usual Care 
N=91 
 MPI 
N=96 
 Mean difference 
(UC-MPI) 
 Effect 
size 
  Mean (SE)* N** Mean (SE)* N** (95%CI) P-value d 
Depression and anxiety scales       
BDI         
 After 1 week 17.31 (0.77) 68 15.45 (0.80) 64 1.85 (-0.36 to 4.06) 0.10 0.29 
 After 3 months 17.57 (0.82) 63 15.59 (0.87) 57 1.98 (-0.39 to 4.36) 0.10 0.31 
 After 9 months 17.96 (0.96) 59 15.04 (1.00) 58 2.92 (0.17 to 5.68) 0.04 0.39 
SCL Anxiety         
 After 1 week 21.43 (0.69) 66 20.76 (0.73) 61 0.67 (-1.31 to 2.64) 0.51 0.11 
 After 3 months 21.66 (0.74) 61 20.87 (0.78) 55 0.79 (-1.34 to 2.91) 0.47 0.14 
 After 9 months 23.54 (0.84) 58 19.85 (0.87) 57 3.69 (1.29 to 6.09) 0.003 0.57 
SGRQ subscales        
Activity subscale        
 After 1 week 70.51 (1.75) 54 62.99 (1.92) 46 7.52 (2.39 to 12.66) 0.004 0.59 
 After 3 months 68.91 (1.86) 48 62.54 (2.07) 41 6.37 (0.87 to 11.87) 0.02 0.49 
 After 9 months 70.64 (2.09) 47 65.32 (2.25) 45 5.32 (-0.78 to 11.43) 0.09 0.37 
Impact subscale        
 After 1 week 44.95 (1.58) 60 41.43 (1.70) 52 3.52 (-1.03 to 8.07) 0.13 0.29 
 After 3 months 46.51 (1.83) 51 40.16 (1.93) 49 6.35 (1.10 to 11.61) 0.02 0.48 
 After 9 months 46.48 (1.96) 50 37.86 (2.03) 49 8.62 (3.04 to 14.21) 0.003 0.62 
Symptoms subscale        
 After 1 week 60.08 (2.53) 64 57.58 (2.67) 57 2.50 (-4.71 to 9.70) 0.50 0.12 
 After 3 months 59.16 (2.61) 58 53.91 (2.84) 48 5.25 (-2.33 to 12.84) 0.17 0.27 
 After 9 months 57.48 (2.67) 54 52.37 (2.75) 52 5.11 (-2.43 to 12.65) 0.18 0.26 
Total SGRQ scale        
 After 1 week 55.63 (1.57) 49 50.48 (1.71) 42 5.14 (0.59 to 9.70) 0.03 0.47 
 After 3 months 56.09 (1.64) 44 49.12 (1.82) 38 6.97 (2.14 to 11.80) 0.005 0.64 
 After 9 months 56.08 (1.86) 42 48.14 (1.98) 42 7.94 (2.67 to 13.32) 0.004 0.65 
Abbreviations: SE, standard error; BDI, Beck Depression Inventory; SCL Anxiety, Symptom Checklist 
Anxiety; SGRQ, Saint George’s Respiratory Questionnaire 
Range of the BDI is 0-63, with 0 as the most favourable outcome; range of SGRQ total scale and 
subscales is 0-100, with 0 as the most favourable score; range of the SCL Anxiety scale is 1-50, with 1 as 
the most favourable outcome. 
*estimates from mixed model regression analyses, corrected for age, gender, level of education and 
baseline value of the outcome measure. 
**The maximum number of patients across measurements for whom imputation of items was not 
possible was 2 for the BDI, 5 for the SCL, 32 for Activity, 21 for Impact, 15 for Symptoms and 41 for the 
SGRQ total score. 
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No effects were found on the SGRQ symptom subscale, but the SGRQ total scores 
showed that, on average, intervention patients had a significantly better quality of life 
than controls at all follow-up measurements (1 wk p=0.03; 3 months p=0.005; 9 months 
p=0.004). In terms of clinical relevance, a four-point change relative to baseline on the 
SGRQ total score was more often seen in intervention patients than in control 
patients at all follow-up measurements, with a significant difference at nine months 
(52% vs. 29%, p=0.03, not tabulated). Effect sizes corresponding to significant results 
can all be classified as medium.30 Additional per-protocol and LOCF analyses pro-
duced similar results (data not shown). 
DISCUSSION 
This study showed that a nurse-led minimal psychological intervention significantly 
reduced depressive symptoms and prevented aggravation of anxiety in elderly COPD 
patients with minor to moderate depression. The intervention also improved disease-
specific quality of life. Corresponding effect sizes were all medium.30 
Our tailor-made intervention was intended to educate patients to take responsibility 
for the day-to-day management of their own illness and its consequences. This was 
achieved by improving patients’ understanding of the relation between their behav-
iour and consequent mood, by challenging them to draw up action plans to change 
their behaviour, and by teaching them self-management skills that they could apply in 
daily life. The study results indicate that the aim of the intervention was indeed 
achieved, as differences between groups became larger over time for all outcomes, 
except for the Activity subscale. This may very well mean that patients learned skills 
and continued to apply them in daily life during the follow-up period, even becoming 
more successful over time. Winning back control over daily symptoms by learning 
coping skills seems very rewarding especially for COPD patients, as many of them 
have developed a tendency towards ‘learned helplessness’ during the course of their 
disease. 
As noted by Coventry & Gellatly in their recent review,16 only a few studies have 
evaluated the effectiveness of psychological treatments for depression and anxiety in 
COPD patients. The effect sizes for symptoms of depression and anxiety found in our 
study are highly similar to those reported by Coventry and Gellatly.16 As regards 
disease-specific quality of life, the group difference of 7.94 for the SGRQ total score in 
our study is higher than the weighted mean difference (WMD) derived from seven 
other studies evaluating self-management (WMD=2.58 ;95% CI-0.02 - 5.14),17 and is 
also larger than the accepted cut-off point (four points) for a clinically relevant 
change.31 Interestingly, whereas previous analyses found no effect on generic quality 
of life,18 we did find an effect on disease-specific quality of life in the current analyses. 
Disease-specific quality of life measures have been shown to be more responsive to 
change than generic measures.32 Since the SGRQ covers specific domains that are 
important to patients with COPD, the use of this measure enabled us to detect 
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changes in quality of life that are of specific importance and relevance to them but are 
beyond the scope of generic instruments. 
Several potential weaknesses of our study should be considered. First, dropouts were 
older and had a lower quality of life and higher levels of depressive symptoms. 
Although dropout was somewhat more common in the intervention group, this 
difference was not statistically significant. Despite the use of mixed models for 
repeated measures (which include patients with incomplete observations), this 
pattern of attrition might have affected our findings. However, an LOCF analysis, 
often regarded as a conservative imputation method,33 did not alter our conclusions. 
Second, disease severity can be an interfering factor if severity is unequally divided 
between groups. We did not have objective data on the severity of COPD among 
participants at baseline, such as FEV1 data, since patient inclusion was done by GPs on 
the basis of existing practice records. However, disease-specific quality of life, which 
has been shown to be related to COPD severity but may reflect disease impact 
better,34 did not differ between groups at baseline. Third, blinding of patients was 
obviously not possible, as we compared the intervention with usual care, as is often 
done in pragmatic trials. 
Our study had several strengths. Suspected depression, as picked up by the screen-
ing questionnaire, was confirmed by a DSM-IV based diagnostic interview. Addition-
ally, we included patients with a wide range of depression severity, so that our sample 
reflects the natural heterogeneity of patients with depressive symptoms in primary 
care. A further strength of our approach is that nurses were used to administer the 
intervention. Since nurses are already involved in disease-management programmes 
and as such see patients on a regular basis, they seem obvious candidates for the task 
of administering psychological interventions. We have shown that nurses without any 
specific psychiatric background can be trained to administer an MPI that successfully 
reduces depression and anxiety and improves quality of life. An extensive process 
evaluation showed that nurses had adhered closely to the protocol and that they were 
highly enthusiastic about the intervention. As for patients, the evaluation revealed 
that they were also highly satisfied with the intervention and would recommend it to 
other persons with a chronic illness.25 Incorporation of our intervention within 
existing disease-management programmes therefore appears a logical next step. By 
taking on the task of depression management within these programmes, nurses may 
thus complement the GP’s regular work. 
CONCLUSION 
In a time when aging of the population is likely to increase the prevalence and 
burden of COPD, maintaining the highest possible quality of life and slowing down 
further deterioration of the COPD patient’s health status will remain the key goals of 
COPD treatment. Our nurse-administered minimal psychological intervention was 
effective in reducing anxiety and depressive symptoms and improving disease-
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specific quality of life. We therefore feel that adding MPI to existing disease-
management programmes is likely to improve the care for elderly COPD patients. 
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ABSTRACT 
Objective: Depression is associated with high healthcare utilization and related costs. 
Effective treatments might reduce the economic burden. The objective of this study 
was to establish the cost-utility of a minimal psychological intervention (MPI) aimed at 
reducing depression and improving quality of life in elderly persons with diabetes or 
chronic obstructive pulmonary disease and co-occurring minor, mild or moderate 
depression.  
Method: Trial-based cost-utility analysis comparing the MPI with usual care. Annual 
costs and quality-adjusted life years (QALYs) based on the Euroqol (EQ5D) and on 
depression-free days were calculated.  
Results: We found improvements, albeit not significant, in clinical outcomes and a 
decrease in mean annual costs in favour of the MPI group. Additional bootstrap 
analysis indicated a dominant intervention, with a probability of 63% that the MPI is 
less costly and more effective than usual care.  
Conclusion: This study tends to support further dissemination of the MPI in regular 
care.  
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Depression is a common disorder in older persons1 and is associated with a reduced 
quality of life,2 increased morbidity,3 and increased physical disability.4 This applies 
especially to older persons with chronic illnesses, such as type II diabetes mellitus 
(DM) and chronic obstructive pulmonary disease (COPD).5 6 Patients with depression 
run the risk of sliding into a downward spiral, since depression and disability are 
mutually reinforcing.4 Depression may impair one’s ability to adhere to medical 
regimens (diet, exercise, quitting smoking, taking medication regularly), potentially 
worsening the course of the chronic illness,7 and may also lead to greater health care 
utilization and related costs.8 9 It is therefore of great importance to develop treat-
ments for chronically ill elderly persons that help reduce the burden of depression. 
This is especially true for the treatment of depression in primary care, since persons 
with depression often present initially to a general practitioner.8 
Although attempts have been made to study the cost-effectiveness of collaborative 
care depression treatment, offering both pharmacological and psychological treat-
ment options,8-11 the societal impact of psychological depression treatment among 
elderly persons with chronic somatic illnesses, incorporating health care costs as well 
as production losses, remains largely unclear.8 The Depression in Elderly with Long-
Term Afflictions (DELTA) study has been designed to evaluate the effectiveness and 
cost-effectiveness of a minimal psychological intervention (MPI) to reduce depression 
and improve quality of life in elderly persons with DM or COPD and co-occurring 
depression. The MPI was carried out by primary care nurses and is based on princi-
ples of self-management and cognitive behavioural therapy (CBT).  
The aim of this article is to assess, from a societal perspective, the cost-effectiveness 
of the MPI compared to usual care. We expected our intervention to lead to an equal 
level of health care utilization as that with usual care, and therefore to equal health-
related costs. In addition, we expected favorable outcomes in terms of quality of life 
and depression, implying a cost-effective intervention. 
METHODS 
Design 
The economic evaluation was embedded in a two-armed randomised controlled trial 
(RCT). A detailed description of the design of the DELTA-study has been published 
elsewhere.12 A block randomisation was used, with stratification for chronic illness 
and the general practice where the patient was registered. We used a block size of 
two, because we expected to include few patients per general practice and wanted 
equal distribution over the groups. The researchers entered each patient’s identifica-
tion number into a computer system connected to an external agency. Patients were 
then randomised by the agency, using a computerized random number generator. 
Data were entered by the researchers, who were blinded for the allocation. Costs and 
effects were assessed at baseline (prior to randomisation) and at three, six, nine (only 
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costs), and twelve months after baseline. The first follow-up in the intervention group 
was one week after the final intervention contact, and depended upon the duration 
of the tailor-made intervention. The economic evaluation was performed from a 
societal perspective, which implies that all relevant costs and effects are taken into 
account.13 Approval for this study was granted by the Medical Ethics Committee of 
Maastricht University/University Hospital Maastricht. 
Participants 
Between October 2003 and May 2005, participants were recruited in 89 primary care 
practices in the south of the Netherlands. Patients with an established diagnosis of 
DM or COPD, aged 60 years and over, who were community-dwelling and did not 
meet exclusion criteria (treatment with antidepressants for depression, major 
psychiatric problems, current psychosocial/psychiatric treatment, serious cognitive 
problems, being on a waiting list for nursing home, being bedridden, loss of spouse 
within the last three months, and not being fluent in Dutch) were sent the Patient 
Health Questionnaire (PHQ-9).14 Patients who reported having at least two symptoms 
of depression present for more than half of the days, one of them being loss of 
interest or depressed mood, were invited to take part in a structured diagnostic 
interview for DSM-IV axis I disorders, the Mini International Neuropsychiatric 
Interview (MINI).15 In addition, the Hamilton Depression Rating Scale (HDRS)16 was 
used to determine the severity of the depression. The MINI and HDRS were adminis-
tered at the patients’ home by trained nurses. Patients with minor depression, mild to 
moderate major depression or dysthymia were invited to participate in the trial. 
Patients with suicidal risk and patients with severe major depression (HDRS>18) were 
excluded and referred to their GP. After signing an informed consent form and 
completing a baseline questionnaire, patients were randomly allocated to the MPI 
(N=183) or usual care (N=178).  
Intervention and usual care 
Patients allocated to the intervention group received the MPI supplementary to usual 
care. The intervention was delivered at the patient’s home by nurses, who were 
trained in the DELTA intervention, based on principles of CBT and self-management, 
but had not received additional training for DM or COPD. The DELTA intervention 
consists of five phases, which have been described in more detail elsewhere.12 17 
Briefly, in phase one, the nurse explores the patient’s feelings, cognitions, and 
behaviours. During phase two, the patient keeps a diary, in which they record 
symptoms, complaints, thoughts, worries, and related feelings and behaviours. In 
phase three, the patient is challenged to link their mood to the consequent behav-
iour, using information from the diary. The self-management approach is introduced 
in phase four, where the patient explores possibilities to alter their behaviour and 
where they draw up an action plan. Phase five consists of an evaluation of the degree 
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to which goals from the action plan have been achieved. The intervention is tailor-
made and a home visit could comprise one or more phases. During the study, 
patients received two to ten visits over a period of at most three months, depending 
on the patient’s progress. The mean number of visits was four, with a mean duration 
of 61 minutes.18 
Patients assigned to usual care received regular treatment according to the practice 
guidelines of their chronic somatic illness. These practice guidelines, produced by the 
Dutch College of General Practitioners, encompass regular check-ups for medical 
symptoms, but do not involve detection and treatment of depressive symptoms.19-21 
Care providers remained blinded for the results of the depression screening for the 
duration of the study. Due to blinding of the care providers and the randomisation, 
co-interventions are supposed to be comparable between intervention and control 
group.  
Measurements 
COSTS 
To establish the costs, relevant cost items were identified, after which these costs 
were measured and values were placed on the cost items.  
We started by identifying program costs, health care costs, patient and family costs, 
and productivity losses. Program costs include the costs that can be attributed to the 
process of developing and administering the MPI, for example the costs of the home 
visits, MPI training for nurses, and nurses’ travel expenses. Research-specific costs, 
such as costs of questionnaires, were excluded. Health care costs in our study were 
all costs related to patients’ visits to a GP’s surgery, hospital care (inpatient and 
outpatient), allied health professionals such as physiotherapists or dieticians, profes-
sional home care, medical devices and assistive devices, and prescribed and over-the-
counter medication. Patient and family costs included costs of informal care (help 
from family and friends) and paid domestic help. Productivity losses consisted of sick 
leave from work and loss of activities in and around the home.  
We then measured the cost categories identified above. The program costs were 
measured by means of a questionnaire in which nurses recorded time spent on home 
visits and travelling. The time spent developing the MPI and training nurses to use it 
was recorded by the researchers. Payroll information was used to calculate the hourly 
wages of nurses, developers, and trainers. Cost diaries22 were used to measure 
volumes of health care utilization, patient and family costs, and productivity losses. 
Patients kept a prospective diary for two weeks at baseline and for four weeks at all 
four follow-up measurements. After each measurement, a telephone operator, 
blinded for allocation, contacted patients to retrieve information from the diary. Data 
were immediately entered in a computer file to ensure efficiency and reliability. 
Finally, the valuation was based on volumes obtained from the cost diary and questi-
onnaires, multiplied by cost prices derived from the updated Dutch manual for 
costing.23 24 Costs due to productivity losses were estimated using the friction cost 
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approach, as described in this manual. Prices of informal care were based on shadow 
prices for unpaid work. Where no standard cost prizes were available, real costs or 
tariffs were used to estimate costs. For example, costs of assistive devices were 
obtained from the market prices of these devices (volumes and cost price details are 
available upon request). Baseline costs were used to examine the comparability of the 
groups at baseline. The total annual costs were determined by extrapolating the costs 
from the available four months of follow-up measurements by three to obtain the 
total costs during twelve months of follow-up. The annual costs are presented in 
Euros and the baseline year was 2004. The discounting rate was 4%.23 24 
EFFECTS 
The generic effects on quality of life were assessed with the Euroqol (EQ5D).25 This 
widely used quality-of-life instrument includes five dimensions of health-related 
quality of life, namely mobility, self-care, daily activities, pain/discomfort and depres-
sion/anxiety. Each dimension was rated at three levels: no problems, some problems 
and major problems. The five dimensions were combined into a health state. Utility 
values were calculated for these health states, using preferences elicited from a 
general Dutch population.26 27 The utility values were used to compute quality-
adjusted life years (QALY-EQ5D) by means of the area under the curve method.28 In 
addition, depression-specific effects were assessed with the Beck Depression 
Inventory (BDI).29 We used the method developed by Lave et al. to calculate depressi-
on-free days (DFD) during follow-up.30 This method uses depression scores from the 
BDI over time to estimate days free of significant depressive symptoms. As suggested 
in previous research, we used a health utility improvement of 0.4 for depression-free 
days to estimate the QALY-DFD.30 31 
The EQ5D and BDI were assessed by means of self-administered questionnaires, sent 
together with the cost diaries, at baseline and at the three, six, and twelve months’ 
follow-up assessments.  
Analyses 
Analyses were based on the intention-to-treat principle. An analysis of baseline 
characteristics and baseline costs examined the comparability of the groups at 
baseline. Persons with effect scores on at least two of the three follow-up measure-
ments and cost data on at least three of the four follow-up measurements were 
included in the analysis. Missing items on the BDI scale were replaced by the individ-
ual’s own mean of non-missing items at that follow-up measurement, if at least half of 
the items for that follow-up were available. This method could not be applied to the 
EQ5D and cost data, since domains of the EQ5D and cost category levels (e.g. hospi-
tal-related costs or costs of informal care) consisted of one item. Therefore, missing 
data on the EQ5D and cost category levels were replaced by the individual’s own 
mean of non-missing data at follow-up measurements. Using person specific mean 
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imputation techniques is considered a valid method for imputation of longitudinal 
data.32 
Because cost data are typically highly skewed, we used bootstrap estimation with 1000 
replications to obtain means and standard deviations of our cost and effect data. The 
differences between the intervention and control groups were estimated by means of 
linear regression, controlling for age, sex, education, chronic somatic illness, and 
baseline value of either the cost category or the effect measure.  
Cost-utility analysis 
To establish the cost-utility of our intervention, we bootstrapped the predicted 
annual total cost and the predicted effects (QALY-EQ5D and QALY-DFD) derived from 
the linear regression models. The incremental cost-utility ratio (ICUR) was calculated 
as: 
 
ICUR = (Ci – Cc) / (Ei – Ec), 
 
where Ci is the adjusted annual total cost of the intervention group, Cc is the ad-
justed annual total cost of the control group, Ei is the adjusted effect for the interven-
tion group and Ec is the adjusted effect for the control group.  
In addition to the primary (QALY-EQ5D) and secondary (QALY-DFD) analyses, we 
evaluated two models to examine the sensitivity of our cost-utility results. First, we 
conducted an analysis in which missing cost data were not imputed (complete case 
analysis). A second sensitivity analysis was performed to test whether a reduction of 
program cost from € 337 to € 282 would change the cost-utility ratio. The reduction of 
program costs was based on a scenario in which patients visit the nurse at the GP’s 
surgery instead of the nurses paying home visits, as was done in our study. This 
scenario is considered to be a suitable alternative when implementing our interven-
tion in routine practice.  
RESULTS 
Of the 361 eligible patients, 183 were assigned to the intervention group and 178 to 
the control group. After imputation, complete data were available for 228 persons 
(control n=118; intervention n=110). These persons were significantly younger (p<.00) 
and had significantly higher utility scores at baseline (p=.01) than persons for whom 
complete follow-up data was not available. No other significant differences in 
characteristics were found between these groups.  
Table 1 shows the baseline characteristics of the intervention and control groups. The 
intervention group had slightly higher costs than the control group in the two weeks 
prior to the intervention, but differences were not significant. Other characteristics 
were comparable between groups.  
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Table 1  Comparability of intervention and control groups in terms of socio-demographic variables and 
baseline values of outcomes 
  Usual Care MPI P-value 
Variable  n=118 n=110  
Age, yrs (SD)  69.98 (6.26) 69.47 (6.17) .54 
Sex, No. (%)    .97 
 Male 63 (53.4) 59 (53.6)  
 Female 55 (46.6) 51 (46.4)  
Chronic illness, No. (%)    .72 
 Diabetes 64 (54.2) 57 (51.8)  
 COPD 54 (45.8) 53 (48.2)  
Education level*, No. (%)    .25 
 Low 41 (34.7) 34 (30.9)  
 Medium 26 (22.0) 35 (31.8)  
 High 51 (43.2) 41 (37.3)  
     
Utility†, mean (SD)  0.63 (0.20) 0.61 (0.22) .35 
     
BDI‡, mean (SD)  17.48 (8.07) 16.73 (7.20) .46 
     
Costs prior 2wk   307 (30) 337 (37) .56 
 mean Euro (SD)     
* Low refers to primary school only, medium refers to lower vocational training or lower general 
education, high refers to higher vocational training, general secondary education, higher professional 
education and university training 
† Based on the Dutch algorithm for the EQ5D scores; utility scores range from 0 (death) to 1 (full health) 
‡ Range of the BDI is 0-63, with 0 as the most favorable outcome 
 
 
Table 2  Mean annual cost per patient* 
 Mean Euro (SD)† P-value‡ 
 Usual care MPI  
Program costs   337 (11)  
Health care related costs 8,082 (833) 7,243 (885) .50 
 GP 471 (31) 550 (53) .10 
 Hospital  3,371 (630) 2,885 (701) .69 
 Allied health professionals 397 (63) 474 (78) .76 
 Professional home care 1,616 (286) 936 (205) .25 
 Medical aids and assistive devices 547 (139) 710 (191) .60 
 Prescribed and OTC medication 1,628 (85) 1,673 (85) .46 
Patient and family costs 472 (74) 497 (98) .62 
 Informal care 281 (66) 410 (91) .61 
 Paid domestic help 192 (42) 81 (30) .01 
Productivity loss 1,194 (234) 1,432 (272) .83 
 Paid work 189 (119) 0 (0) .14 
 Unpaid work 1,014 (208) 1,442 (283) .42 
Total costs 9,770 (890) 9,549 (1,059) .53 
* Volumes and cost price details are available upon request 
† Unadjusted bootstrapped mean and standard deviation 
‡ Based on linear regression corrected for age, sex, chronic somatic illness, education, and baseline 
cost 
ECONOMIC EVALUATION 
 117 
Annual costs and clinical effects 
The control group had slightly higher costs than the intervention group  
(€ 9,770 vs. € 9,549; Table 2). Hence, a cost saving was achieved in the intervention 
group, despite the extra costs (on average €337) of the MPI in the intervention group. 
However, the overall cost difference was not significant, although a significant 
difference was found in costs of paid domestic help, in favour of the group that 
received the MPI (€ 192 vs. € 81; p=.01).  
Linear regression of the clinical effects revealed a significant difference between 
utilities derived from the EQ5D at the final follow-up measurement (p=.02). However, 
no significant differences between utilities were found at the other follow-up meas-
urements. In addition, no significant differences in mean QALY-EQ5D or mean QALY-
DFDs were found between patients from the intervention and control groups, 
although outcomes were all in favour of the intervention group (Table 3). 
 
 
Table 3  Clinical effects 
 Mean (SD)* P-value† 
 Usual Care MPI  
 n=118 n=110  
QALY – EQ5D‡  0.59 (0.02) 0.62 (0.02) .06 
 Utility at three monthsc 0.61 (0.02) 0.64 (0.02) .10 
 Utility at six monthsc 0.59 (0.02) 0.61 (0.02) .33 
 Utility at twelve monthsc 0.56 (0.02) 0.62 (0.02) .02 
QALY – DFD§ 0.78 (0.01) 0.80 (0.01) .31 
 DFD / yeard 163 (11) 184 (12) .31 
* Unadjusted bootstrapped mean and standard deviation 
† Based on linear regression corrected for age, sex, chronic somatic illness, education, and baseline 
EQ5D or BDI score 
‡ Based on the Dutch algorithm for EQ5D scores 
§ Based on the BDI scores 
 
Cost-utility 
Because patients receiving the MPI had lower costs and experienced greater health 
effects, the MPI dominated usual care (Table 4). The ICUR of the primary analysis 
showed a saving of € 11,508 per QALY-EQ5D (95% CI -160,502 to 192,027). The ICUR of 
the secondary analysis showed a saving of € 12,534 per QALY-DFD (95% CI -190,366 to 
101,049). The cost saving per depression-free day was €14 (95% CI -157 to 106; data not 
shown). 
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Figure 1  Cost-effectiveness plane: mean cost difference between the MPI and usual care groups (vertical 
axis) and mean effect difference (horizontal axis). 
 
Bootstrap replications of the ICUR were performed to address the uncertainty 
surrounding this ratio. The results of the primary analysis, using the QALY-EQ5D, are  
presented in a cost-effectiveness plane (Figure 1), with differences in cost on the 
vertical axis and differences in effects on the horizontal axis. Each dot (n=1,000) 
represents a bootstrap replication. The distribution of our primary analysis shows that 
63% of the dots are in the lower right-hand quadrant, indicating a probability of 63% 
that our MPI is the dominant treatment, because the MPI is less costly and more 
effective than care as usual (see also Table 4). In addition, 28% of the dots are located 
in the upper right-hand quadrant, indicating that a health gain is produced, but at 
additional costs. On the other hand, there is a probability of 5% that the MPI is 
inferior (upper left-hand quadrant) and 4% that the MPI is less costly but also less 
effective (lower left-hand quadrant). The percentage of dominance for the secondary 
analysis, based on DFDs, is slightly higher (67%; Table 4) than that in our primary 
analysis. 
Interpretation of these outcomes also depends on how much decision-makers are 
willing to pay for each quality-adjusted-life-year gained. For instance, if a decision-
maker is willing to pay € 20,000 per QALY gained, the probability of the MPI being 
cost-effective is about 82% (see dotted line in Figure 1 and Figure 2). 
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Figure 2  Cost-utility acceptability curve: probability that the MPI is cost-effective (vertical axis) given 
various ceiling ratios for willingness to pay (horizontal axis). 
 
In Dutch health care, this ceiling ratio is often considered a reasonable critical level 
for QALY cost.33 A Dutch advisory committee to the Ministry of Health even proposed 
a ceiling ratio of € 80,000 per QALY gained,34 which would result in an 89% probability 
of our intervention being superior to care as usual. This is further illustrated in the 
cost-effectiveness acceptability curve of our primary analysis (Figure 2). The probabil-
ity of our intervention being superior to usual care (y-axis) is shown for varying ratios 
for willingness to pay for each quality-adjusted-life-year gained.35 36  
The sensitivity analyses, both the complete case analysis and the analysis with a 
reduction of program costs, indicated that results of our primary analysis were robust 
(Table 4). Both ICURs showed dominance, and the probabilities of the intervention 
being dominant were largely the same as in our primary analysis. In the complete case 
analysis, however, the probability of the MPI being less effective and less costly 
increased, while the probability of the MPI being more costly but also more effective 
decreased. As expected, a reduction of program costs led to an increase in dominan-
ce, since the costs in the intervention group were lower, while the effects remained 
the same.  
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Table 4  Incremental cost-utility ratio and percentage of dominance 
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Primary analysis  
QALY – EQ5D 
118 110 Dominance 28 5 4 63 
   (-160,502-192,027)     
Secondary analysis  
QALY – DFD 
118 110 Dominance 29 2 2 67 
   (-190,366-101,049)     
Sensitivity analyses        
 Complete case analysis 58 65 Dominance 3 5 30 62 
    (-687,933-357,800)     
 
Reduction of program 
costs† 
118 110 Dominance 23 5 4 68 
   (-158,691-143,458)     
ICUR = incremental cost-utility ratio; CI = confidence interval 
* MPI compared to usual care based on 1,000 bootstrap replications. 
† Reduction of program cost from € 337 to € 282, based on scenario where patients visit general practice 
instead of home visits 
DISCUSSION 
In this group of elderly patients with DM or COPD and co-occurring minor, mild to 
moderate major depression or dysthymia, our minimal psychological intervention will 
probably lead to improvements in quality of life and depression-free days, and a 
decrease in mean annual costs. In our study, the MPI proved to be the dominant 
treatment, which is supported by the cost-effectiveness acceptability plane showing a 
63% probability that the MPI is less costly and more effective than usual care. If 
decision-makers are willing to pay € 20,000 per QALY gained, the probability increases 
to 82%. Sensitivity analyses showed that our findings are robust; the probability of a 
cost-effective intervention remained largely the same.  
Limitations of this study include the attrition rate. This could have influenced our 
findings, especially because persons who dropped out of the analysis tended to be 
older and had poorer quality of life at baseline. However, attrition was not signifi-
cantly different between the intervention and control groups. We used person 
specific mean imputation techniques to address issues of missing data. This method is 
considered valid,32 although more refined techniques might have provided better 
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estimates.37 A complete case analysis showed that our imputation techniques may 
have caused a higher probability of our intervention being cost-effective. A second 
limitation is the poor validity of the DFD method to establish cost-utility.31 Cost-utility 
analyses have been introduced to provide a generic outcome measure for the 
comparison of costs and effects across diseases.13 However, the cost-utility estimate 
of the DFD method is not based on generic outcomes but on depression severity, 
making it invalid for comparison with other diseases than depression. Nevertheless, 
we decided to include the DFD method as a secondary analysis, to be able to com-
pare our results with those of studies using the DFD method. A third limitation 
concerns the generalisability of our findings across the two chronic somatic illnesses. 
We added chronic somatic illnesses to our regression models, but the individual cost-
effectiveness outcomes for diabetic and COPD patients remain unclear, as our study 
population was too small for disease-specific analyses. Fourth, we used a cost diary to 
assess the cost data. This method has some advantages over questionnaires, because 
it measures healthcare consumption prospectively and might be more accurate.22 38 
However, cost diaries often have relatively high levels of missing values. Finally, to 
reduce the burden for the patients, we measured discontinuous. Previous studies 
revealed that measuring in at least three months during a year provides good esti-
mates of annual costs.22 39 Nevertheless, high one-time expenses, such as inpatient 
hospital stays, might be missed or overestimated by measuring discontinuously. Also, 
the estimate of the QALY would have been more precise is we had used more 
measurement times.  
While reviewing our results, one should take into account that differences in clinical 
effects, in terms of QALYs, were not significant between the intervention and control 
groups. However, the utility scores showed a significant difference at the final follow-
up. An increase in differences over time has also been found for the depression 
parameter in our effectiveness study.40 Since our intervention is a short, cognitive 
behavioural skill based program, the most plausible explanation would be that 
patients gained skills to cope with depression and used them more and more in daily 
life. Therefore, the difference in effect may become more pronounced at longer 
follow-up. The lack of significant cost differences in our study had been anticipated: 
the goal of our intervention was not to reduce health care utilization, but to improve 
the quality of life for patients with a chronic somatic illness. In the long run, however, 
improvement of the health-related quality of life could lead to a reduction of health 
care utilization. Our cost analysis shows that the most considerable cost savings were 
in favour of the intervention group, and a longer follow-up might show a further 
reduction of health care utilization.  
Our study found a cost saving of € 14 per depression-free day. According to a review 
by Wang et al., most other studies found an additional cost per depression-free day 
ranging from € 7 to € 26, instead of a cost saving.9 However, none of these studies 
focused on persons with chronic somatic illnesses. Recently, two additional studies 
were published that focused on depression treatment of persons with DM.41 42 In line 
with our findings, these studies found beneficial cost-effectiveness outcomes, 
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although both studies only reviewed health care related costs, not including produc-
tion losses, and had a follow-up of twenty-four months instead of twelve months.  
One of our sensitivity analyses was based on an implementation scenario in which 
patients visit a GP’s surgery to receive the MPI instead of nurses visiting patients at 
home. In the Netherlands, primary care nurses are increasingly employed in general 
practice to treat persons with chronic somatic illnesses. Therefore, detection and 
monitoring of depressive symptoms and, if necessary, depression treatment could 
easily be integrated in regular care. This scenario seems to be a good alternative to 
home visits by nurses exclusively providing depression treatment, especially if health 
care insurers are willing to invest in an improved quality of life for persons with 
chronic somatic illnesses. Results of our process evaluation,18 effectiveness evalua-
tion,40 and this cost-utility study support further dissemination of our MPI for elderly 
persons with a chronic illness.  
Our findings suggests that treatment of depression with our minimal psychological 
intervention in persons with a chronic somatic illness probably leads to improve-
ments in quality of life and depression-free days at no greater cost than care as usual, 
implying a cost-effective intervention. These results support further dissemination of 
the MPI, for example in disease management programs for persons with chronic 
somatic illnesses.  
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This thesis described the effectiveness and cost-effectiveness of a nurse-led Minimal 
Psychological Intervention in reducing depressive symptoms and improving quality of 
life in chronically ill elderly patients. Furthermore, the validity of a depression 
screening questionnaire was evaluated. This chapter discusses the main findings of 
the study, including a reflection on methodological and conceptual considerations, 
the generalizability of the study results, a comparison with other studies and implica-
tions of the findings. Finally, recommendations for future research and an overall 
conclusion will be formulated. 
MAIN FINDINGS 
Regarding the main research question, we found that the MPI was both effective and 
cost-effective. The MPI was found to have a significant positive effect on depressive 
symptoms and this effect was found to be generic across DM and COPD, which 
answers the second research question (Chapter 4). The effect sizes were small to 
medium and a positive trend of increasing differences between groups over time was 
observed. The chance of improvement of depressive symptoms, defined as a reduc-
tion of baseline depression score with 50% or more, was thrice as high in the inter-
vention group as in the control group. The MPI also had a significant effect on generic 
quality of life in diabetic patients at the last follow-up with a medium effect size and 
with the same pattern of increasing between-group differences over time (Chapter 4). 
The cost-effectiveness study provided important information for health policy makers 
and health care insurers and showed that with a probability of 63%, the MPI is less 
costly and more effective than usual care (Chapter 7). If decision makers would be 
willing to pay € 20,000 per Quality Adjusted Life Year (QALY) gained, this probability 
would increase to 82%. A cost saving of €14 per depression-free day was found. 
Besides collecting data on depression and quality of life outcomes, data on several 
disease-specific outcomes were collected during follow-up. We found that the MPI 
also had an effect on these disease-specific outcome measures. On a COPD-specific 
quality of life measure, we found significant effects in favour of the intervention, with 
medium effect-sizes. Effects were largest on the Impact subscale, which covers social 
functioning and psychological disturbances resulting from COPD, and again, be-
tween-group differences increased over time. Anxiety is also common in COPD 
patients. The intervention had a significant effect on symptoms of anxiety in COPD 
patients; control patients on average had more symptoms of anxiety than intervention 
patients during follow-up (Chapter 6). In diabetic patients, significant effects on 
diabetes-specific quality of life were only found in certain subgroups (Chapter 5). 
Higher educated patients, male patients and patients with a shorter duration of 
diabetes benefited from the intervention. Hba1c levels, an indicator of glycemic 
control, of patients receiving the intervention decreased over time, indicating a better 
glycemic control. In control patients, an opposite pattern was observed in Hba1c 
levels, and this difference in trend between groups was statistically significant. 
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In the study evaluating the validity and reliability of the Patient Health Questionnaire-
9 (PHQ-9) depression screening questionnaire (Chapter 3), we found that the PHQ-9 
was a reliable instrument in elderly with a chronic somatic disease. The validity of two 
scoring methods for the PHQ-9 was evaluated. The first method was the algorithm-
based score, which is a dichotomous outcome based on the DSM-IV criteria for 
depression (at least 5 symptoms and at least one core symptom present). The second 
method was the summed score, which sums the score of all nine items and ranges 
from 0 to 27. The validity of this summed PHQ-9, using the Mini International Neuro-
psychiatric Interview (MINI) as reference, was found to be good. The algorithm-based 
PHQ-9 score on the other hand, had low sensitivity meaning that it missed a high 
percentage of depressed cases. Low sensitivity was due to the underreporting of the 
two core symptoms of depression on the PHQ-9, namely depressed mood and loss of 
interest or pleasure. The fact that patients felt reluctant to report these psychological 
symptoms, but not to report somatic symptoms, may indicate that the fear of being 
stigmatized is still present in elderly populations. 
Overall, with respect to the research questions, we have shown that the MPI is 
effective in reducing depressive symptoms and improving quality of life in chronically 
ill elderly, with consistent patterns of increasing differences over time. This supports 
the theory that over time, patients in the intervention group continued to use the 
skills they had learned in the intervention in their daily lives, leading to less depres-
sive symptoms in the long-term. Furthermore, there is a high probability that the 
intervention does not cost more than care as usual, but even leads to a cost saving, 
and is therewith cost-effective. It can therefore be concluded that the MPI seems well 
suited for implementation within regular care and existing disease-management 
programmes, improving the care for chronically ill elderly persons.  
METHODOLOGICAL AND CONCEPTUAL CONSIDERATIONS 
Selection and attrition bias 
Bias in trials may occur as a result of non-response or loss to follow up.1 Bias may 
affect the external validity and consequently the generalisability of the findings, or 
affect internal validity which may lead to an over- or underestimation of the effect of 
the intervention. In our study, participants in the diagnostic interview (MINI) and 
non-participants did not differ significantly on demographic characteristics or PHQ-9 
depression score, so chances of a potential bias at this stage seem unlikely. Persons 
who participated in the DELTA study however, were younger and significantly higher 
educated than eligible persons who refused to participate. This may have led to 
selection bias with an overrepresentation of higher educated and younger persons; 
the consequences of this will be discussed in a later section. 
Attrition may lead to an imbalance in characteristics of groups, threatening the 
internal validity, and may limit the external validity when attrition is selective. It is 
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therefore important to take measures to prevent attrition or missingness of data and 
to choose proper methods of analyses. In the DELTA-study, efforts were taken to keep 
patients in the study. Patients who did not wish to receive the intervention or discon-
tinued the intervention were encouraged to continue to fill in the follow-up ques-
tionnaires or at least fill in the final follow-up questionnaire. Control patients who 
wanted to stop participating in the trial were likewise encouraged to fill in the last 
questionnaire. Attrition rates up to 30% are not uncommon in populations of elderly 
with a chronic disease and increasing age is associated with attrition.2 3 In the DELTA-
study, approximately 33% of the participants dropped out. Attrition bias may have 
occurred as drop-outs were significantly older than those remaining in the study and 
this may have affected external validity. The variables age, gender and educational 
level were standard included in the models to reduce the chance of bias caused by 
imbalances in these variables between groups. Furthermore, the use of mixed-effects 
models in the data analyses may have reduced the influence of attrition bias, as this 
technique uses all available data. It does not delete persons with missing observa-
tions, nor does it imputes measurements.4 It therefore thought to be the preferable 
method in the analysis of repeated measurements and is valid under the missingness 
mechanism of missing at random (MAR), which is thought to be a reasonable assump-
tion in clinical trials and was assessed likely to be the case in our study.5 6 
MTA methodology 
Outcomes from MTA research are an important information source in the decision-
making processes of policymakers and health care insurers. With methodology 
stemming from economic theories, this relatively young research area is a constantly 
developing one. Especially in terms of statistical methods, much has improved over 
the last decade.7 
In our cost-effectiveness study, we used both quality-adjusted-life-years (QALYs) and 
depression-free days (DFDs) as outcome measures for the effects of the MPI. Over 
the last few years, the DFDs method as outcome measure of effect is increasingly 
used in depression research.8-11 However, the use of this DFD method is under 
discussion.12 Normally, the outcome measure for the effects of a treatment is a 
generic outcome. This allows for the comparison with other treatments and condi-
tions, which is important for decision makers in health care. The DFD method is not a 
generic outcome and results can therefore only be compared with other depression 
treatment studies using this method. DFDs can further be used to estimate QALYs. In 
theory, these DFD-QALYs can be used for comparison with other treatments and 
conditions. However, as long as the validity of the method used to calculate DFDs and 
QALYs from DFDs remains unclear, it is not advisable to compare DFD-based QALYs 
with QALYs based on generic outcomes. Despite the concerns about the validity of 
the DFD-method, we decided to include DFDs to make comparison with other studies 
using the DFD-method possible.  
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Minor depression: to treat or not to treat 
Minor depression is increasingly thought to be on a continuum with major depres-
sion.13 14 Epidemiological studies have supported the view that depression is a 
dynamic disorder, evolving on a continuous scale.15 16 Studies have further shown that 
patients with minor depression are at higher risk of developing major depression 
compared to non-depressed persons,17 18 and spontaneous remission rates of minor 
depression are low.19 In light of preventive strategies, it would have been interesting 
to evaluate whether the MPI can prevent new cases of major depression. In our study, 
however, we were not able evaluate whether the intervention had a preventive effect, 
as we did not use a diagnostic depression instrument in the data collection at follow-
up. Nevertheless, intervention patients had a threefold higher chance of improving 
their depression severity with 50% or more compared to baseline than controls. Since 
the intervention seems to have a strong effect on the reduction of depressive symp-
toms, a preventive effect on developing major depression seems likely. 
The notion of a continuum of depression has also received criticism; where does 
everyday unhappiness end and where does a clinical disorder begin? In light of the 
‘medicalisation of unhappiness’ the need of treatment of minor depression is often 
questioned. By accepting minor depression as a disorder, we run the risk of overtreat-
ing persons. Especially with antidepressant treatments the treatment may be worse 
than the condition itself, given the chance of side effects and, in chronically ill elderly, 
the possible interaction with other medication.20 Nevertheless, the number of studies 
evaluating antidepressants for minor depression increases steadily.21-26 Further, in the 
late nineties, GPs often prescribed antidepressants in less severe cases of depression 
where the use of antidepressants was not indicated by clinical guidelines.27 Another 
problem with starting active treatment in minor depression is the stigmatization that 
persons may experience when they are labelled as having minor depression. It is 
known that patients, in reaction to expected discrimination, remain secretive about 
their condition and treatment or withdraw from social life. This may have negative 
consequences for their social support network and self-esteem.28 In clinical guide-
lines,29 30 minor depression currently is not included and in current literature, watch-
ful waiting strategies or activating patients into pleasant activities are proposed as 
suitable strategies for minor depression.23 31 Watchful waiting only requires action 
from the GP and activation can be presented to the patient as a general advice 
without labelling the patient as minor depressive. These strategies seem sensible, 
since both approaches are non-invasive, and do not involve labelling and stigmatisa-
tion. However, in some cases of minor depression, more active forms of treatment 
seem feasible and advisable. As our study showed, patients who are at high risk of 
developing major depression, like persons with chronic somatic diseases, may benefit 
from minimal strategies aiming to improve coping and self-management skills. These 
interventions can be introduced as skill-enhancing, can be incorporated within 
disease management programs, and do not necessary need to be labelled as ‘depres-
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sion treatment’, which reduces the chance of stigmatisation of patients receiving such 
treatment. 
GENERALIZABILITY 
The DELTA study was designed as a pragmatic randomised controlled trial. In a 
pragmatic trial, the effectiveness of a new treatment in everyday clinical practice is 
evaluated.32 Inclusion and exclusion criteria are kept to a minimum to assure good 
external validity. A relatively heterogeneous study population forms a representative 
sample of patients that would be considered for the treatment in routine primary 
care. A downside to pragmatic trials is that the effort to ensure external validity may 
be at the expense of internal validity.33 For instance, in pragmatic trials, patients are 
not always blinded and this may introduce bias. In our study, certain measures were 
taken to ensure internal validity; randomisation was performed by an external agency, 
blinded for the researchers and during data entry researchers were not aware of 
treatment allocation. 
Even though the pragmatic character of the DELTA-study ensures high external 
validity, there are limitations to the generalizability of the results. In our sample, 
younger and higher educated patients were somewhat overrepresented due to 
attrition and selection bias. As previously mentioned, patients with a lower education 
potentially experience less benefit from the intervention.34 This means that in daily 
practice, where the population on average is lower educated than the population in 
the trial, the effects of the MPI overall may be lower than the effects observed in the 
trial. Furthermore, we did only include persons with diabetes and COPD, and al-
though the effect of the intervention on depressive symptoms was comparable, we 
can not blindly assume that it will be as effective in other chronic disease as well. 
However, others have shown that the type of chronic disease does not influence 
treatment outcome.35-37 Furthermore, many self-management approaches advocate 
the generality of their program. For instance, Lorig’s Chronic Disease Self-
Management Program (CDSMP) is given in mixed groups with the underlying as-
sumption that persons with a chronic disease all face the same adaptive tasks.38 Also, 
data from the process evaluation showed that patients who received MPI in our study 
would recommend the intervention to patients with other chronic diseases as well.39 
These findings support the view that the MPI is likely to be successful in patients with 
other chronic diseases as well. 
In the current cost-effectiveness analyses, costs of screening, diagnosing and moni-
toring patients were not included. Although the results of the cost-effectiveness study 
are favourable, with a high probability of a cost-effectiveness intervention, the cost-
saving found in our study will be lower in real life settings, as it will take time and thus 
money to screen, diagnose and monitor patients. 
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FINDINGS DELTA IN LIGHT OF PREVIOUS FINDINGS 
In the Netherlands, several studies have evaluated (short) psychological treatments 
compared to usual care in primary care settings. A study that included patients with 
minor depression found that minimal-contact psychotherapy reduced depressive 
symptoms and lowered the incidence of major depression.40 Other studies focusing 
on major depression or mental health problems, found that psycho-educational 
prevention plus CBT had an effect on depressive symptoms in major depression,41 
while interpersonal psychotherapy and nurse-administered problem-solving therapy 
only seemed to be effective in more severe cases of major depression and mental 
health problems.42 43 
In recent years, many depression trials have focused on collaborative care (e.g. 
IMPACT, PROSPECT, PATHWAYS).44-46 Collaborative care interventions are multifac-
eted organizational interventions aimed at major depression and involve the collabo-
ration of a general practitioner, case manager and a mental health specialist, and 
often use algorithm-stepped depression care. Meta-analysis has shown that collabora-
tive care is more effective than standard care, with a mean effect size of 0.31 at twelve 
months.47 Cost-effectiveness studies have shown that collaborative care costs €7 to 
€26 per depression-free day,48 and two studies in diabetes patients also found cost 
savings, but only after 24 months.11 49 In comparison, the intervention in the DELTA-
study had an effect size of 0.29 at approximately 12 months after inclusion and 
showed a cost saving of €14 per depression-free-day over a 12 month period. How-
ever, when comparing, findings, one should keep the differences between the DELTA 
study and collaborative care studies in mind. The collaborative care studies were 
aimed at major depression while we aimed our intervention at patients with minor 
depression and mild-to moderate major depression. Further, different cost-
perspectives were used. We used a societal perspective, which is much broader than 
the payers’ perspective used in collaborative care studies. The contrast between the 
treatment arms was also probably different in these studies than in our study, as there 
are likely to be differences in the standard of usual care, access to care and number of 
patients that is being treated according to clinical guidelines between the Nether-
lands and the United States. Also, in the DELTA study, physicians were not notified of 
participants’ depression status, whereas in IMPACT, PROSPECT and PEARLS, physi-
cians were informed. The fact that in DELTA, improvement rates in the control group 
were only 10 percent, may have been caused by the fact that GPs did not recognise or 
treat depression in these patients during follow-up. Nevertheless, taking into account 
the differences between studies, our results are certainly remarkable, considering 
that collaborative care is an organisational intervention that is usually offered for a 
longer time period (e.g. IMPACT offered the improved care for 12 months), and our 
minimal intervention was a patient-aimed intervention with on average four one-hour 
contacts. 
In a recent meta-analysis of treatment for late-life depression, CBT was found to have 
an effect size of 0.88,50 which is much larger than our findings. However, differences 
in setting, duration and intensity of CBT may account for the discrepancy between 
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DELTA results and result from this meta-analysis. The cost-effectiveness of psycho-
logical treatments for depression, like CBT and problem-solving therapy, has not yet 
been fully be established, although some studies have suggested that nurses can 
provide cost-effective treatments.51 Our cost-effectiveness results add to the body of 
evidence of the cost-effectiveness of nurse-administered treatments. 
IMPLICATIONS AND RECOMMENDATIONS 
Results from the validation study of the PHQ-9 point to an underreporting of depres-
sive symptoms, especially the core symptoms of depression (depressed mood and 
loss of interest). This implicates that stigma on depression may still be very much alive 
in older persons. Patients often present only the somatic symptoms of depression and 
these somatising persons are less willing to mention psychological symptoms.52 53 
Education can reduce the stigma on depression in older persons and should be 
directed to patients as well as and their relatives. It should be made clear that depres-
sion is a disorder and not a result of personal failure. There is however, also the side 
of the GP to consider. It is known that GPs sometimes perceive late-life depression as 
a natural consequence of ageing and having chronic conditions and therefore do not 
initiate treatment. Education may be well in place here to bring down these preju-
dices. But GPs may also make errors in the diagnostic process. Especially in the 
presence of a chronic somatic disease, GPs may feel reluctant to ascribe somatic 
symptoms to a depressive disorder. However, research showed that is it not advisable 
to discount somatic symptoms in the diagnosis of depressive disorder in older 
persons with somatic diseases.54 On the other hand, diagnosing depression is not just 
the mere counting of symptoms. Assessing the impact of symptoms on daily function-
ing (social functioning, occupational functioning etc.) is as important as knowing 
whether symptoms are present. Nevertheless, symptom checklists like the (summed) 
PHQ-9 may serve as a first filter in the diagnostic process and may facilitate health 
care professionals in making a depression diagnosis. 
In the DELTA study, we did not only find positive results for the effectiveness and 
cost-effectiveness of the MPI, but also in the process evaluation. Results from this 
extensive process evaluation showed that both patients and nurses were highly 
satisfied with the intervention.39 This accumulation of evidence supports the imple-
mentation of the intervention in the regular care for diabetes and COPD. However, 
before actions for implementation can be taken, certain matters need to be resolved. 
For instance, the population at risk needs to be defined, a protocol to detect patients 
with depressive symptoms and a monitoring system for patients need to be devel-
oped, the training and certification of nurses needs to be professionalised, and 
possible adaptations to the programme need to be explored. First, to which group of 
patients will the intervention be offered to in primary care? The current study focused 
on elderly patients, but younger patients (<60 years) struggling with the conse-
quences of their disease may benefit from the intervention as well. Also, patients with 
chronic diseases other than diabetes or COPD may benefit from the intervention. It 
would be recommended to start implementation for elderly diabetic and COPD 
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patients within regular care and disease management programmes, and include 
younger patients when experiences are positive. In a later stadium, the MPI may then 
be introduced to disease management programs for other conditions. Second, how 
are patients with depressive symptoms identified? Given the underreporting of core 
symptoms of depression, the summed PHQ-9 score would be useful for depression 
screening in chronically ill elderly patients. In patients with a positive screening 
outcome, the symptoms and impact on daily functioning should be checked by the 
nurse, and medical causes like hypothyroidism ruled out, which may imply that 
patients need a consultation with their GP before the nurse can start administering 
the MPI. Other criteria need to be protocolised as well; rules for referral to special-
ized care of patients with suicidal ideation, major psychiatric comorbidity or cognitive 
decline need to be formed. Third, a monitoring system should be developed with 
clear guidelines regarding the frequency and manner of monitoring depressive 
symptoms after conclusion of the intervention, and on what to do in case of non-
response to treatment or deterioration. It would be advisable for nurses to include 
the topic of depressive feelings in every subsequent visit of the patient to the clinic. 
When a patient seems to have deteriorated in terms of depressive symptoms, one or 
two booster-sessions can be offered, in consultation with the patient and, if neces-
sary, the GP. If a depression becomes severe or a patient develops suicidal ideations, 
direct referral to the GP or specialized mental health care should take place. Fourth, 
the training for nurses to administer the intervention should be professionalised. The 
intervention demands from nurses a change in their attitude towards patients; they 
are, for instance, not supposed to provide a direct solution to a patients’ problem but 
rather encourage patients explore possible solutions themselves. Not all nurses will 
be capable of making this attitude change. Therefore, requirements which nurses 
should meet before receiving a certificate need to be defined. Training and certifica-
tion should preferably be done through universities of professional education, for 
example by offering specialized learning modules in the official nursing curriculum. 
Also, revision and booster sessions need to be organized for nurses working with the 
intervention. Finally, the results from the diabetic population indicate that not all 
diabetics benefit equally from the intervention in terms of disease-specific outcomes. 
Only men, patients with a diabetes duration <7 years and higher educated persons 
showed benefit from the intervention in terms of diabetes-related emotional distress 
and diabetes symptom burden. Also, results from DELTA-data and a study of Gum et 
al., indicated that lower educated patients may not benefit equally from psychological 
interventions as their higher educated counterparts.34 55 Areàn and colleagues 
reported that care managers in a depression treatment trial noted that persons with a 
lower income required more case management services (referrals to social services, 
acquiring transportation) than persons with a higher income, suggesting that different 
groups of patients may want to address different problems.56 The differential treat-
ment effect that was found in the DELTA study may be explained by differences in the 
type of problems that patient addressed and possibly the ability of patients to project 
the learned skills to other domains of their lives. For instance, if patients have more 
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difficulties in finding their way within the health care system or have difficulties in 
providing themselves with basic needs (housing, transportation), they may want to 
address these issues first. Since our MPI is very minimal, problems arising from 
consequences of their disease may not have been addressed during the intervention. 
Patients with a lower ability to project may be unaware of the possibilities to apply 
their skills to other domains and this may limit the beneficial effects of the interven-
tion. It would be interesting to determine whether there is indeed a difference in the 
type and domain of problems that are addressed during the MPI between persons 
who benefited and those who did not. Future research evaluating interventions with a 
problem-solving component should collect data on the type of problems that was 
addressed, as this will provide answers to which kind of adaptations can be made to 
the intervention in order to achieve maximum benefit in these groups. 
The intervention evaluated in the DELTA-study was based on cognitive behavioural 
therapy (CBT) and self-management. By teaching patients how to deal with the 
consequences of their chronic disease, their coping skills and level of self-efficacy 
and mastery are thought to increase. These improved skills will improve their daily 
functioning and will also affect depressive symptomatology. Although we have shown 
that depressive symptoms were reduced by the intervention, we yet need to deter-
mine what the influence of the MPI was on coping, self-efficacy and mastery, and to 
which extent these factors mediated the effect of the intervention on depressive 
symptoms. 
Evaluating the effect of depression treatment on the course of a chronic disease may 
be complicated, as the relationship between chronic disease and depression is a 
complex one. Although in the last few years, many studies have focused on depres-
sion treatment in chronically ill persons, much of the interacting effects remain 
unknown. It is thought that chronic somatic illness may cause a worsening of depres-
sion through the functional impairments associated with the somatic disease. It may 
also worsen depression through indirect pathophysiologic effects on the brain (via 
inflammatory markers).57 Depression in turn may influence the chronic disease 
through behaviours (non-adherence to treatment) but also through biological 
pathways. Depression itself is associated with chronic inflammatory changes; depres-
sion enhances the production of pro-inflammatory cytokines. This may aggravate or 
induce chronic diseases.57 Since low-grade inflammation plays a role in both chronic 
diseases and depression, it would be worthwhile to evaluate to which extent depres-
sion treatments can influence inflammatory markers and to which extent this affects 
the chronic illness as well. Further, as effective depression treatment may improve 
treatment adherence, disease-specific measures are interesting outcome measures in 
trials with chronically ill persons. Next to evaluating adherence to treatment regimens 
and self-care behaviours, measures like symptoms burden, the number of complica-
tions over time and disease-specific biomarkers (e.g. HbA1c) can provide a valuable 
insight to the extent to which depression treatments have a preventive effect on the 
worsening of the chronic disease. Studies with a longer follow-up are needed to 
study these potential long-term effects. 
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CONCLUSION 
Depression is a highly prevalent and disabling disorder which can have strong 
negative consequences for elderly with chronic diseases. However, it is often not 
recognised or treated in primary care. 
Findings from the DELTA-study indicate that the PHQ-9 summed score in the screen-
ing for depression may serve as a first filter to identify chronically ill elderly with a 
depression. Skill-enhancing minimal strategies like our Minimal Psychological 
Intervention (MPI) can then be offered to persons with non-severe cases of major 
depression and minor depression. 
The MPI that was evaluated in the DELTA-study appeared an effective, cost-effective 
and feasible treatment for diabetic and COPD patient with co-occurring minor 
depression or mild to moderate major depression. The intervention also had a 
positive effect on COPD and diabetes-specific outcomes. As nurses were able to 
administer this minimal strategy successfully, adding the MPI to regular care and 
existing disease-management programs is likely to lead to improvements in the care 
for chronically ill elderly persons and to improvements in the patient’s health status. 
Before implementation activities can be started, protocols for screening, initiating 
treatment and monitoring of patients need to be formed. Also, the training and 
certification for the MPI should be included in the course offerings for nurses. 
Future research should focus on long-term effects of depression treatment on the 
course of chronic illnesses and on getting more insight in the interactions between 
depression and chronic diseases and the contribution of inflammatory markers 
therein. 
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Summary 
 
As the population ages, the health care system is facing an increasing number elderly 
persons with a chronic somatic disease, which in turn will increase the health care 
costs. Keeping patients in an optimal condition and preventing further disabilities are 
important goals in the treatment; however, co-occurring depression may push 
patients into a downward spiral and may accelerate the disablement process. Depres-
sion in chronically ill elderly often remains undetected and untreated in primary care. 
Major depression leads to lower quality of life, higher morbidity and mortality and is 
accompanied with higher health care costs and health care utilization. This also holds 
for minor depression, which is a sub-clinical form of major depression. Psychological 
treatments based in cognitive behavioural therapy (CBT) or self-management are 
preferable in chronically ill elderly persons over antidepressants. They provide lasting 
skills which may be of benefit in later stages of their disease and minimal formats may 
be acceptable in milder forms of depression as well, while the effectiveness of 
antidepressants in milder forms of depression has not been thoroughly established. 
The DELTA study (Depression in Elderly with Long-Term Afflictions) aimed to improve 
the detection and treatment of minor depression and mild to moderate major 
depression in chronically ill elderly persons. In a randomised controlled trial, a nurse-
led Minimal Psychological Intervention, based on CBT and self-management princi-
ples, was compared with care as usual. Aims of the study that were addressed in this 
thesis were 1) to evaluate both the effectiveness and cost-effectiveness of the nurse-
led Minimal Psychological Intervention (MPI) in reducing depressive symptoms and 
improving quality of life in elderly diabetic and chronic obstructive pulmonary 
disease (COPD) patients with a co-occurring minor to moderate depression, 2) to 
evaluate whether the effect of the MPI was generic across DM and COPD patients, 3) 
to evaluate the effect on COPD and diabetes-specific outcome measures, and 4) to 
test the reliability and validity of the Patient Health Questionnaire-9 (PHQ-9) that was 
used for depression screening. 
 
Chapter 2 of this thesis describes the design of the DELTA study. Within 89 primary 
care practices in the south of the Netherlands, diabetic and COPD patients aged 60 
year and over were screened for depression using a short depression screening 
questionnaire (Patient Health Questionnaire-9 - PHQ-9). Patients with a positive 
screening were invited to a diagnostic interview (Mini International Neuropsychiatric 
Interview – MINI) to confirm the depression diagnosis. Eligible patients were then 
invited to participate in the trial and were randomised. Data on the primary outcomes 
and on costs were further collected at one week, three, six (cost data only) and nine 
months after the intervention. 
 
In Chapter 3, the reliability and validity of the PHQ-9 screening questionnaire were 
assessed. To assess reliability, a test-retest was conducted in 105 elderly diabetic and 
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COPD patients. For the evaluation of the validity, data of 713 persons were available. 
Construct validity was assessed by calculating the correlation of PHQ-9 scores with 
scores on quality of life and disease severity measures. To assess criterion validity, 
sensitivity and specificity of the PHQ-9 were calculated for both the summed PHQ-9 
score as well as the algorithm based PHQ-9 score, using the MINI diagnostic inter-
view as the gold standard. Results from this study indicated that the PHQ-9 is a 
reliable instrument in elderly populations with diabetes or COPD. The construct 
validity of the PHQ-9 in this population was found acceptable. Further it was found 
that the algorithm based PHQ-9 score had high specificity but low sensitivity, indicat-
ing that it missed a larger percentage of depressed cases. The summed PHQ-9 score 
however, had both high sensitivity and specificity, and should be preferred over the 
algorithm based PHQ-9 score in screening elderly diabetic and COPD patients. 
 
Chapter 4 presents the effects of the intervention on depressive symptoms and 
quality of life and provides an answer to the question whether or not the effects of 
the MPI are generic across diseases. In total, 361 patients with diabetes type II and/or 
COPD were included in the study and were randomly allocated to the nurse-led MPI 
or usual care. At baseline, groups were comparable in terms of demographic and 
socio-economic factors and on the outcomes depressive symptoms (Beck Depression 
Inventory) and quality of life (Short Form-36). During the trial, 33% of the patients 
dropped out but drop-out was non-differential between groups. The MPI had a 
positive effect on depressive symptoms, with increasing differences over time and a 
significant difference at nine months after the intervention. Patients receiving the 
intervention were also three times more likely to show a reduction of 50% or more of 
baseline depressive symptoms. The effect on depressive symptoms was found to be 
generic across diseases. The intervention further had an effect on quality of life, 
although this was only observed in the diabetic patients. 
 
Chapter 5 describes the effect of the MPI on diabetes-specific outcomes. Of the total 
DELTA-population, 208 patients had diabetes type II (185 DM only; 23 also with COPD) 
and were included in the analysis. Outcome measures used were diabetes symptom 
distress (Diabetes Symptoms Checklist-Revised), emotional distress (Problem Areas in 
Diabetes) and glycemic control. For glycemic control, HbA1c data were collected from 
primary care and hospital records, and were available for 135 persons. As results of 
analyses on symptom and emotional distress showed only limited effects, sub-group 
analyses indicated that the intervention had a significant effect on both symptom and 
emotional distress in higher-educated with medium to large effect sizes, but not in 
lower-educated patients. Further, we found a significant effect of the intervention on 
symptom distress in men, and on emotional distress in patients with a diabetes 
duration<7 years. The intervention further had an effect on glycemic control. A 
significant difference in trend over time was observed, with a significantly lower mean 
HbA1c level in the intervention group compared with the control groups at nine 
months after the intervention (between-group HbA1c difference 0.5%). As these 
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results indicate that not all groups of patients benefited equally from the intervention, 
further exploration is necessary. 
 
Chapter 6 reports on the effects of the intervention in COPD patients. Outcomes 
measures used were COPD-specific quality of life (Saint George’s Respiratory 
Questionnaire), depressive symptoms (Beck Depression Inventory) and symptoms of 
anxiety (Symptom Checklist). Anxiety was included because COPD patients often 
experience anxiety and we expected the intervention to influence symptoms of 
anxiety as well. In total, 187 COPD patients (176 COPD only; 11 also with diabetes) 
were included in the analyses. The intervention group on average had significantly 
less symptoms of depression and anxiety at nine months after the intervention than 
the control group. Although in earlier analyses no effects were found on generic 
quality of life in COPD patients (Chapter 5), these analyses showed that the interven-
tion did have significant effects on COPD-specific quality of life, with medium-sized 
effects. 
 
In Chapter 7, the results from the economic evaluation are presented. Such informa-
tion is of great value to policy makers and health insurers. To evaluate cost-
effectiveness and cost-utility, data on all relevant costs were collected, including 
program costs, health care costs, patient and family costs, and productivity losses. For 
the effect estimate, quality-adjusted life years based on the EuroQol-5 and on depres-
sion-free days were calculated. Two-hundred and twenty-eight persons were in-
cluded in the analyses. Results indicated that between-group differences in effect and 
in costs were in favour of the intervention, although differences were not significant. 
Bootstrap analyses of the incremental cost-utility ratio revealed that the intervention 
was dominant, with a 63% probability that the intervention is both more effective and 
less costly than usual care. 
 
Finally, in Chapter 8, the main results are put into a broader perspective. First a 
summery of the main results is given and answers to the research questions are 
provided. Overall, the nurse-led Minimal Psychological Intervention was found both 
effective and cost-effective and the effect on depressive symptoms was generic across 
diabetes and COPD. The summed PHQ-9 score was found to be a reliable and valid 
tool for screening elderly diabetic and COPD patients for depression. Dissemination 
of the intervention in regular care or existing disease-management programs seems 
the logical next step, although certain issues around target population, monitoring 
and training of nurses need to be addressed. Topics for the future research agenda 
include the assessment of the long-term effects of depression treatment on the 
course of chronic illnesses and the interaction between depression and chronic 
somatic disease. 
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Samenvatting 
 
Door de vergrijzing van de populatie, zal er een toename komen van het aantal 
ouderen met een chronische ziekte en zullen tevens de kosten voor de gezond-
heidszorg stijgen. Om verdere invaliditeit van patiënten te voorkomen, is het daarom 
van belang om chronisch zieke ouderen in een zo optimaal mogelijke gezondheids-
toestand te houden. Een depressie kan er echter voor zorgen dat mensen in een 
neerwaartse spiraal terecht komen en dit kan het invaliditeitsproces versnellen. In de 
eerstelijnszorg wordt bij chronisch zieke ouderen depressie vaak niet herkend of 
behandeld. Depressie leidt tot een slechtere kwaliteit van leven, hogere morbiditeit 
en mortaliteit en gaat gepaard met hogere gezondheidszorgkosten en zorggebruik. 
Hetzelfde geldt voor de lichte, subklinische vorm van depressie. De behandeling van 
depressie met psychologische interventies, zoals cognitieve gedragstherapie (CBT) en 
zelfmanagement, zijn te prefereren boven behandeling met antidepressiva, omdat 
mensen door psychologische behandelingen vaardigheden ontwikkelen die van 
blijvend nut kunnen zijn. Ook zijn psychologische behandelingen voor mensen met 
mildere vormen van depressie acceptabeler dan antidepressiva, waarvan de werking 
in mildere vormen van depressie nog niet goed is vastgesteld. De DELTA studie 
(Depression in Elderly with Long-Term Afflictions) beoogde de herkenning en 
behandeling van depressie bij chronisch zieke ouderen te verbeteren. In een geran-
domiseerde studie werd een Minimale Psychologische Interventie (MPI), die ge-
baseerd was op CBT en zelfmanagement principes en werd gegeven door een 
verpleegkundige, vergeleken met gebruikelijke zorg. Doelen van de studie die zijn 
behandeld in dit proefschrift waren (1) het evalueren van de effectiviteit en kostenef-
fectiviteit van de MPI in het verminderen van depressieve symptomen en het verbe-
teren van de kwaliteit van leven van ouderen met diabetes type II of chronisch 
obstructieve pulmonaire aandoeningen (COPD) die tevens lichte tot matige depressie 
hadden, (2) het evalueren of het effect van de MPI generiek is over diabetes en COPD 
patiënten, (3) het evalueren van de effecten van de MPI op COPD- en diabetes-
specifieke uitkomstmaten en 4) het evalueren van de betrouwbaarheid en validiteit 
van de Patient Health Questionnaire-9 (PHQ-9) die in de DELTA studie werd gebruikt 
om mensen met depressie op te sporen. 
 
Hoofdstuk 2 van dit proefschrift beschrijft de opzet van de DELTA studie. Alle 
diabetes en COPD patiënten van 60 jaar en ouder uit 89 huisartspraktijken in Zuid-
Limburg werden gescreend op depressie door middel van een korte screenings-
vragenlijst (PHQ-9). Patiënten met een positieve screening werden uitgenodigd voor 
een diagnostisch interview (Mini International Neuropsychiatric Interview – MINI) om 
de diagnose depressie te bevestigen. Geschikte patiënten werden daarna uitgeno-
digd deel te nemen aan het onderzoek. Dataverzameling door middel van schrifteli-
jke vragenlijsten en kostendagboekjes vond plaats bij instroom in het onderzoek, één 
week na de behandeling, en drie, zes en negen maanden na behandeling. 
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Hoofdstuk 3 beschrijft de betrouwbaarheid en validiteit van de Patient Health 
Questionnaire-9 (PHQ-9) in een oudere populatie diabetes en COPD patiënten. Om 
de betrouwbaarheid van deze korte screeningsvragenlijst te bepalen werd een test-
hertest uitgevoerd onder 105 oudere diabetes en/of COPD patiënten. Voor het 
bepalen van de validiteit werd gebruik gemaakt van gegevens van 713 ouderen met 
diabetes en/of COPD. Construct validiteit werd bepaald door het berekenen van 
correlaties tussen de PHQ-9 en scores op uitkomstmaten als kwaliteit van leven en 
ziekte-ernst. Om criterium validiteit vast te stellen werd de sensitiviteit en specificiteit 
van de PHQ-9 berekend, voor zowel de somscore als de algoritme-gebaseerde score 
van de PHQ-9, waarbij de MINI als gouden standaard werd gebruikt. Uit de resultaten 
bleek dat de PHQ-9 een betrouwbaar screeningsinstrument voor depressie is bij 
ouderen met diabetes of COPD. De construct validiteit van de PHQ-9 was acceptabel. 
Betreffende de criterium validiteit werd gevonden dat de het algoritme-gebaseerde 
PHQ-9 score een hoge specificiteit had, maar een lage sensitiviteit, wat betekent dat 
er veel mensen met een depressie onopgemerkt bleven. De somscore van de PHQ-9 
had zowel een hoge sensitiviteit als en een hoge specificiteit en zou daarom geprefe-
reerd moeten worden boven de algoritme-gebaseerde score bij gebruik van de PHQ-
9 bij ouderen met diabetes of COPD. 
 
In Hoofdstuk 4 worden de resultaten van de effecten van de interventie op de-
pressieve symptomen en kwaliteit van leven gepresenteerd en wordt tevens een 
antwoord gegeven op de vraag of de effecten generiek zijn over de ziektes. In totaal 
werden 361 patiënten met diabetes type II of COPD in het onderzoek ingesloten en 
willekeurig toegewezen aan de interventiegroep die de Minimale Psychologische 
Interventie (MPI) van de verpleegkundige ontving of aan de controlegroep die 
gebruikelijke zorg kreeg. Bij aanvang van de studie waren beide groepen goed 
vergelijkbaar wat betreft demografische en sociaaleconomische factoren en ver-
gelijkbaar wat betreft scores op de uitkomstmaten depressieve symptomen (Beck 
Depression Inventory) en kwaliteit van leven (SF-36). Gedurende het onderzoek viel 
33% van de patiënten uit, maar de uitval was niet verschillend tussen de interventie 
en controlegroep. De MPI bleek een positief effect te hebben op depressieve 
symptomen, waarbij het verschil in depressieve symptomen tussen beide groepen 
groter werd met de tijd en op negen maanden na de interventie statistisch significant 
was. Ook hadden patiënten in de interventiegroep een driemaal hogere kans om een 
vermindering van depressieve symptomen van 50% of meer door te maken dan 
patiënten in de controlegroep. Het effect was tevens generiek over beide chronische 
ziektes. De interventie had tevens een effect op kwaliteit van leven, alhoewel dit 
alleen in diabetes patiënten werd waargenomen. 
 
Hoofdstuk 5 omschrijft de effecten van de interventie op diabetes-specifieke uit-
komstmaten. Van de totale DELTA-populatie hadden 208 patiënten diabetes type II 
(185 alleen DM; 23 naast DM ook COPD), en deze 208 patiënten werden gebruikt in 
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de analyses. De uitkomstmaten waren (hinder van) specifieke diabetes klachten 
(Diabetes Symptom Checklist-Revised), diabetes specifieke emotionele problemen 
(Problem Areas In Diabetes) en glycemische controle. Voor analyses op glycemische 
controle werden HbA1c waarden van deelnemers opgevraagd in huisartspraktijken 
en het ziekenhuis indien beschikbaar; dit was voor 135 patiënten het geval. Omdat 
analyses in de totale diabetes-populatie slechts een beperkt effect van de interventie 
liet zien, werden subgroepanalyses uitgevoerd. Uit deze subgroepanalyses bleek dat 
de interventie een significant effect had op (hinder van) diabetes klachten en emo-
tionele problemen in hoger opgeleide patiënten met matige tot grote effecten, maar 
niet in lager opgeleide diabetes patiënten. Tevens werd gevonden dat de interventie 
bij mannen een significant effect had op (hinder van) diabetes klachten, en bij 
patiënten met minder dan 7 jaar diabetes een significant effect had op emotionele 
problemen. De interventie bleek ook een positief effect te hebben op glycemische 
controle. Er werd een significant verschil gevonden in de trend van Hba1c over tijd, 
met een significant lagere Hba1c waarde in de interventiegroep na 9 maanden 
(verschil HbA1c groepen 0.5%). Omdat de resultaten van deze studie indiceren dat 
niet iedereen evengoed profiteert van de interventie, is verdere exploratie naar 
werkzaamheid in verschillende groepen diabetes patiënten noodzakelijk. 
 
Hoofdstuk 6 beschrijft de effecten van de interventie op COPD patiënten. Als 
uitkomstmaten werden gebruikt: COPD-specifieke kwaliteit van leven (Saint George’s 
Respiratory Questionnaire), depressieve symptomen (Beck Depression Inventory) en 
symptomen van angst (Symptom Checklist). Angst werd meegenomen omdat COPD 
patiënten vaak gevoelens van angst ervaren en omdat verwacht werd dat de interven-
tie ook op angst invloed zou hebben. In totaal werden 187 COPD patiënten in-
gesloten in de analyse (176 alleen COPD; 11 naast COPD ook diabetes). Uit de 
analyses bleek dat patiënten in de interventiegroep gemiddeld minder symptomen 
van depressie en angst hadden dan patiënten uit de controlegroep. Dit verschil was 
significant op 9 maanden na de behandeling. Alhoewel er in eerdere analyses geen 
effecten van de interventie werden gevonden op generieke kwaliteit van leven in 
COPD patiënten (Hoofdstuk 5), werden in de analyses van COPD-specifieke kwaliteit 
van leven wel significante effecten gevonden, met gemiddelde effect groottes. 
 
In Hoofdstuk 7 worden de resultaten van de economische evaluatie beschreven. 
Informatie over kosteneffectiviteit van een behandeling is belangrijk voor beleids-
makers en verzekeraars. Voor het evalueren van kosteneffectiviteit en kostenutiliteit 
werden gegevens over alle relevante kosten verzameld, inclusief programma kosten, 
gezondheidszorgkosten, patiënt en familiekosten en productiviteitsverlies. Voor de 
effect schatting werden quality-adjusted life years berekend op basis van de EuroQol-
5 en op depressie-vrije dagen. Er werden 228 personen in de analyses ingesloten. 
Analyses lieten verschillen zien in kosten en effecten tussen interventiegroep en 
controlegroep in het voordeel van de interventiegroep, maar de verschillen waren 
niet significant. Bootstrap analyses van de incrementele kostenutiliteits-ratio wezen 
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uit dat de interventie dominant was met een 63% waarschijnlijkheid dat de interventie 
effectiever is dan gebruikelijke zorg tegen lagere kosten. 
 
Tot slot worden in Hoofdstuk 8 de resultaten in een breder perspectief geplaatst. 
Eerst wordt een samenvatting van de gevonden effecten gegeven die een antwoord 
geven op de onderzoeksvragen. De Minimale Psychologische Interventie, uitgevoerd 
door een verpleegkundige, bleek zowel effectief als kosteneffectief te zijn. Het effect 
van de interventie op depressieve symptomen was generiek over beide chronische 
ziekten (DM en COPD). De PHQ-9 somscore bleek een betrouwbare en valide 
methode te zijn om te screenen op depressie in ouderen met diabetes of COPD. 
Disseminatie van de interventie in de gebruikelijke zorg of in bestaande disease-
management programma’s lijkt de volgende logische stap. Er dienen echter eerst een 
aantal zaken rondom de doel-populatie, monitoring en opleiding van verpleegkundi-
gen te worden aangepakt. Toekomstig onderzoek zou zich onder andere moeten 
richten op het evalueren van effecten van depressiebehandeling op langere termijn 
en de invloed op het beloop van de onderliggende chronische aandoening, evenals 
de interactie tussen chronische ziekten en depressie. 
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